procarbazine has been researched along with Brain Neoplasms in 332 studies
Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Adding temozolomide (TMZ) to radiation for patients with newly-diagnosed anaplastic astrocytomas (AAs) is common clinical practice despite the lack of prospective studies demonstrating a survival advantage." | 9.22 | The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. ( Abuali, I; Grossman, SA; Lu, Y; Strowd, RE; Ye, X, 2016) |
| "To evaluate tumor responses, event-free survival (EFS), overall survival (OS), and toxicity of chemotherapy, children with neurofibromatosis type 1 (NF1) and progressive low-grade glioma were enrolled into the Children's Oncology Group (COG) A9952 protocol and treated with carboplatin and vincristine (CV)." | 9.22 | Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group. ( Ater, JL; Booth, TN; Freyer, DR; Mazewski, CM; Packer, RJ; Pollack, IF; Sposto, R; Vezina, G; Xia, C, 2016) |
| "Thalidomide and procarbazine have demonstrated single agent activity against malignant gliomas (MG)." | 9.16 | A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas. ( Case, D; Ellis, TL; Enevold, G; Lesser, GJ; McMullen, KP; McQuellon, RP; Rosdhal, R; Ruiz, J; Shaw, EG; Stieber, VW; Tatter, SB, 2012) |
| "To evaluate the feasibility of 1-(4-amino- 2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) of pre-treated procarbazine for elderly patients with newly diagnosed glioblastomas." | 9.12 | Feasibility and response to 1-(4-amino-2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride chemotherapy with pre-treated procarbazine for elderly patients with newly diagnosed glioblastoma. ( Abe, T; Miyagi, N; Ogo, E; Shigemori, M; Terasaki, M, 2007) |
| "The authors investigated the results of PCV chemotherapy within a cohort of 24 patients treated within the EORTC study 26971 on temozolomide chemotherapy in recurrent oligodendroglioma." | 9.11 | Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. ( Allgeier, A; Brandes, AA; Enting, RH; Frenay, M; Kros, JM; Menten, J; Stege, EB; Taphoorn, MJ; Tosoni, A; Triebels, VH; van den Bent, MJ; van Heuvel, I, 2004) |
| "Temozolomide (TMZ) is an oral alkylating agent with a good safety profile and proven efficacy in the treatment of malignant glioma." | 9.10 | Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. ( Foster, T; Newlands, ES; Zaknoen, S, 2003) |
| "To conduct a Phase II study to evaluate the long-term efficacy and safety of high-dose 5'-bromodeoxyuridine (BrdU) and accelerated radiotherapy followed by procarbazine, lomustine (CCNU), and vincristine (PCV) chemotherapy in patients with glioblastoma multiforme." | 9.09 | A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. ( Bruner, JM; Groves, MD; Hess, K; Jaeckle, KA; Kyritsis, AP; Levin, VA; Maor, MH; Meyers, C; Peterson, P; Sawaya, RE; Yung, WK, 1999) |
| "To determine whether chemotherapy with temozolomide (TMZ) versus procarbazine (PCB) for recurrent glioblastoma multiforme (GBM) was associated with improvement in health-related quality of life (HRQOL)." | 9.09 | Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. ( Brada, M; Osoba, D; Prados, M; Yung, WK, 2000) |
| "A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse." | 9.09 | A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. ( Albright, RE; Brada, M; Bruner, J; Fink, K; Fredericks, R; Friedman, H; Glantz, M; Greenberg, H; Hohl, RJ; Levin, VA; Olson, J; Osoba, D; Phillips, P; Prados, MD; Rampling, R; Selker, RG; Shapiro, W; Spence, A; Vick, NA; Yue, N; Yung, WK; Zaknoen, S, 2000) |
| "Although the efficacy of the nitrosourea-based combination chemotherapy procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, and vincristine (PCV) has been previously demonstrated in the setting of anaplastic/intermediate-grade gliomas, the benefit for glioblastoma patients remains unproven." | 9.09 | Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. ( Bruner, JM; Chang, SM; Choucair, A; Flynn, PJ; Gleason, MJ; Hess, KR; Jaeckle, KA; Kyritsis, AP; Levin, VA; Prados, MD; Uhm, JH, 2000) |
| "The aims of this phase I study in patients with recurrent malignant gliomas were to determine the maximum tolerated dose (MTD) and toxicity profile of fotemustine when combined with a fixed dose of procarbazine (PCZ), and to evaluate the extent of O6-alkylguanine-DNA alkyltransferase (ATase) depletion in circulating lymphocytes during treatment." | 9.09 | Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte 06-alkylguanine-DNA alkyltransferase activity. ( Berger, E; Boiardi, A; Ciusani, E; Giroux, B; Lucas, C; Margison, G; Silvani, A; Watson, A, 2001) |
| "To conduct a Phase II one-arm study to evaluate the long-term efficacy and safety of accelerated fractionated radiotherapy combined with intravenous carboplatin for patients with previously untreated glioblastoma multiforme tumors." | 9.08 | Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. ( Bruner, J; Kyritsis, AP; Leeds, N; Levin, VA; Maor, MH; Rodriguez, L; Sawaya, R; Thall, PF; Woo, S; Yung, WK, 1995) |
| "A prospective phase II study of paclitaxel was performed in adult patients with recurrent hemispheric oligodendrogliomas." | 9.08 | Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. ( Chamberlain, MC; Kormanik, PA, 1997) |
| "Twenty six (17 males) patients with glioblastoma (GBL), median age 55 years, median Karnofsky Index (KI) 70/100, and 11 patients (9 males) with anaplastic astrocytoma (AA), median age 56 years, median KI 70/100 were treated at recurrence with dibromodulcitol (DBD) 1400 mg/m2 on day 1, BCNU 150 mg/m2 on day 2, and procarbazine (PCZ) 150 mg/day on days 1 to 15." | 9.08 | Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine--a phase-II study. ( De Witte, O; Hildebrand, J; Sahmoud, T, 1998) |
| "Previous investigators have reported responses in 52% of patients treated with mechlorethamine (nitrogen mustard), vincristine, and procarbazine (MOP) for recurrent glioma." | 9.08 | Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results. ( Buckner, JC; Burch, PA; Dinapoli, RP; Galanis, E; Mailliard, JA; Morton, RF; Novotny, PJ; Rowland, KM; Schaefer, PL; Scheithauer, BW; Vukov, AM, 1998) |
| "The regimen of procarbazine, CCNU, and vincristine is active against gliomas." | 9.08 | Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas. ( Cornetta, K; Dropcho, E; Heilman, DK; Jakacki, RI; Jamison, C; Macdonald, DR; Mathews, VP; Williams, DA, 1998) |
| "In a study activated in 1983 and closed in 1987, the Brain Tumor Research Center of the University of California and the Northern California Cancer Center evaluated the effect of bromodeoxyuridine in the treatment of glioblastoma multiforme." | 9.07 | Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study. ( Ahn, DK; Davis, RL; Flam, MS; Gutin, PH; Levin, VA; Phillips, TL; Prados, MD; Wara, WM; Wilson, CB, 1991) |
| " The protocol called for a randomized trial that compared the effects of following 60 Gy radiation/oral hydroxyurea treatment with either carmustine (BCNU) or the combination of procarbazine, lomustine (CCNU), and vincristine (PCV) for two histologic strata: glioblastoma multiforme and other anaplastic gliomas." | 9.06 | Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. ( Davis, RL; Gutin, PH; Hannigan, J; Levin, VA; Silver, P; Wara, WM; Wilson, CB, 1990) |
| "The majority of patients with high-risk lower grade gliomas (LGG) are treated with single-agent temozolomide (TMZ) and radiotherapy despite three randomized trials showing a striking overall survival benefit with adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy and radiotherapy." | 9.05 | Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. ( Atkins, KM; Dietrich, J; Loeffler, JS; McDuff, SGR; Oh, KS; Shih, HA, 2020) |
| "Within 3 weeks of definitive surgery, 609 patients with histologically demonstrated, supratentorial malignant glioma were randomized to receive, in addition to 6000 rads of radiotherapy, one of four treatment regimens: carmustine (BCNU), high-dose methylprednisolone, procarbazine, or BCNU plus high-dose methylprednisolone." | 9.05 | Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. ( Alexander, E; Batzdorf, U; Brooks, WH; Byar, DP; Green, SB; Hunt, WE; Mealey, J; Odom, GL; Paoletti, P; Pistenmaa, DA; Ransohoff, J; Robertson, JT; Selker, RG; Shapiro, WR; Smith, KR; Strike, TA; Walker, MD; Wilson, CB, 1983) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 8.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| "The methylhydrazine derivative Procarbazine (PCZ) as monotherapy or in combination with CCNU and vincristine (PCV) was evaluated in a vast number of clinical trials and is still used in patients with high-grade and low-grade gliomas." | 8.84 | Procarbazine--a traditional drug in the treatment of malignant gliomas. ( Bogdahn, U; Goerne, R; Hau, P, 2008) |
| " In this paper we address different clinical outcomes measures separately and we illustrate the value of multiple outcome measures using the results of a recent clinical trial comparing temozolomide with procarbazine in the treatment of Glioblastoma Multiforme." | 8.82 | Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. ( Kiebert, G; Macdonald, DR; Olson, J; Prados, M; Yung, A, 2005) |
| "The authors report the clinical features of hypersensitivity reactions believed to result from procarbazine in eight patients treated with mechlorethamine, vincristine, and procarbazine (MOP) for high-grade glioma." | 8.78 | Hypersensitivity reactions to procarbazine with mechlorethamine, vincristine, and procarbazine chemotherapy in the treatment of glioma. ( Bushunow, P; Coyle, T; Graziano, S; Winfield, J; Wright, J, 1992) |
| " Here we describe the occurrence of pseudoprogression in patients with anaplastic oligodendrogliomas treated with postoperative procarbazine, lomustine and vincristine (PCV) chemotherapy alone." | 8.31 | T2-Fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone. ( Boutet, C; Carpentier, C; Dehais, C; Di Stefano, AL; Ducray, F; Esparragosa Vazquez, I; Figarella-Branger, D; Forest, F; Larrieu-Ciron, D; Meyronet, D; Ndiaye, M; Picart, T; Rivoirard, R; Seyve, A; Vassal, F; Younan, N, 2023) |
| "IDH-mutant anaplastic astrocytomas (AAs) are chemosensitive tumors for which the best choice of adjuvant chemotherapy between procarbazine, lomustine, and vincristine (PCV) or temozolomide (TMZ) after radiotherapy (RT) remains unclear." | 8.02 | Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort. ( Bronniman, C; Carpentier, C; Ciron, DL; Dehais, C; Ducray, F; Esteyrie, V; Figarella-Branger, D; Martin, E; Moyal, EC; Network, P; Pouessel, D; Uro-Coste, E, 2021) |
| "Following optimal local therapy, adjuvant Procarbazine, Lomustine and Vincristine (PCV) improves overall survival (OS) in low-grade glioma (LGG)." | 8.02 | One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre. ( Aslam, R; Breathnach, OS; Coyne, Z; Grogan, L; Hennessy, BT; Hennessy, MA; Keogh, RJ; Morris, PG, 2021) |
| "Systematic evaluation of the effectiveness and safety of combined procarbazine, lomustine, and vincristine for treating recurrent high-grade glioma." | 7.96 | A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis. ( Cai, Y; Jiang, YG; Jiang, ZH; Tan, ZG; Wang, M, 2020) |
| "Radiotherapy with procarbazine, lomustine, and vincristine (PCV) improves overall survival in patients with anaplastic oligodendroglioma 1p19q codeleted." | 7.88 | Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted. ( Castro-Martinez, E; Gonzalez-Aguilar, A; Guerrero-Juarez, V; Gutierrez-Aceves, A; Hernandez-Hernandez, A; Lopez-Martinez, M; Peiro-Osuna, RP; Reyes-Moreno, I; Santos-Zambrano, J, 2018) |
| " Among these tumors, a high percentage of low-grade oligodendrogliomas (ODG) are sensitive to chemotherapy with procarbazine, CCNU, and vincristine (PCV)." | 7.73 | Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. ( Branle, F; De Witte, O; Goldman, S; Sadeghi, N; Tang, BN; Wikler, D, 2005) |
| "We have reported that carmustine (BCNU) and cisplatin administered before, during, and after radiotherapy did not improve the survival of patients with high-grade astrocytomas and were associated with more serious toxicities than radiotherapy plus BCNU." | 7.73 | Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma. ( Jung, SM; Liau, CT; Tseng, CK; Wei, KC, 2005) |
| "To assess the feasibility and the activity, as well as the efficacy to treat meninges, of chemotherapy (CHT) containing high-dose methotrexate (HD-MTX) followed by radiation therapy (RT), without intrathecal CHT, in patients with primary central nervous system lymphoma." | 7.71 | Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients. ( Bernardi, M; Camba, L; Ciceri, F; Dell'Oro, S; Ferreri, AJ; Ponzoni, M; Reni, M; Spina, M; Terreni, MR; Tomirotti, M; Villa, E, 2001) |
| "We have studied the effects of medroxyprogesterone acetate (MPA) on C6 glioma growth in vitro in order to prove the hypothesis that it could arrest growth and induce drug sensitisation in a glial tumour as it does in breast cancer cells." | 7.71 | Medroxyprogesterone acetate alone or synergistic with chemotherapy suppresses colony formation and DNA synthesis in C6 glioma in vitro. ( Altinoz, MA; Bilir, A; Onar, FD; Ozar, E; Sav, A, 2001) |
| "The authors reviewed the results of neoadjuvant (preradiation) procarbazine, CCNU, and vincristine chemotherapy for anaplastic oligodendrogliomas because, increasingly, chemotherapy is prescribed before radiation for oligodendroglial neoplasms." | 7.70 | Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. ( Cairncross, JG; Macdonald, DR; Paleologos, NA; Vick, NA, 1999) |
| "A case of successful combination chemotherapy using vincristine, procarbazine, VP-16 and prednisolone to treat an inoperable low grade astrocytoma is presented." | 7.70 | Successful combination chemotherapy (vincristine, procarbazine, etoposide, and prednisolone) in the treatment of inoperable, radioresistant low grade astrocytoma: a case report. ( Janjindamai SHirunpat, S; Maipang MVasiknanonte, P, 2000) |
| "Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy." | 7.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
| "Effective chemotherapy using PCV (procarbazine, lomustine and vincristine) has been documented in anaplastic oligodendrogliomas and oligoastrocytomas." | 7.69 | [Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma]. ( Bouffet, E; Bret, P; Helfre, S; Jouvet, A; Mertens, P; Mornex, F; Sindou, M; Thiesse, P, 1997) |
| "We compared sequential single-agent BCNU and procarbazine (PCB) chemotherapy in 31 patients with gliomas [grade IV (10), grade III (15), grade II (6)]." | 7.68 | Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas. ( Bromberg, J; Greenberg, HS; Junck, L; Newton, HB; Page, MA, 1993) |
| "Twenty-one patients with metastatic melanoma were treated synchronously with procarbazine and radiotherapy." | 7.67 | Effective palliation of melanoma with procarbazine and radiotherapy given by a low-dose fractionation schedule. ( Abbott, RL; Ahmad, A; Gill, PG; Zeicmanis, J, 1986) |
| "Fourteen consecutive melanoma patients with evaluable metastatic disease were treated with combination chemotherapy including procarbazine, vincristine and lomustine (POC)." | 7.67 | Metastatic malignant melanoma treated with procarbazine, vincristine and lomustine (POC). ( Ardizzoni, A; Grimaldi, A; Repetto, L; Rosso, R; Sertoli, MR, 1987) |
| "Twenty consecutive patients with supratentorial Grade III and IV astrocytomas were treated with postoperative radiotherapy, and a simultaneous induction chemotherapy with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), procarbazine, bleomycin, and maintenance chemotherapy with CCNU." | 7.66 | Radiotherapy combined with procarbazine, bleomycin, and CCNU in the treatment of high-grade supratentorial astrocytomas. ( Greiner, RH; Markwalder, H; Seiler, RW; Zimmerman, A, 1978) |
| "2 cases of recurrent medulloblastomas are described who both responded to vincristine alone and in combination with procarbazine." | 7.66 | Response to vincristine and Procarbazine of recurrent medulloblastomas. Report of 2 cases. ( Fricker, U; Reichenbach, W; Seiler, RW; Wagner, HP, 1978) |
| "Seventeen patients with recurrent medulloblastoma were treated with a combination of three drugs: procarbazine, CCNU, and vincristine (PCV)." | 7.66 | Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine. ( Crafts, DC; Edwards, MS; Levin, VA; Pischer, TL; Wilson, CB, 1978) |
| "Anaplastic oligodendroglioma are chemotherapy-sensitive tumors." | 6.78 | Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. ( Allgeier, A; Bernsen, HJ; Brandes, AA; Delattre, JY; Dinjens, WN; Enting, RH; Frenay, M; French, PJ; Gorlia, T; Grisold, W; Hoang-Xuan, K; Kouwenhoven, MC; Kros, JM; Lacombe, D; Sipos, L; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ; Vecht, CJ, 2013) |
| "Intrinsic subtypes are highly prognostic in EORTC 26951 and improve outcome prediction when combined with other prognostic factors." | 6.78 | Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC stu ( de Rooi, J; den Dunnen, WF; Eilers, PH; Erdem-Eraslan, L; French, PJ; Gorlia, T; Gravendeel, LA; Idbaih, A; Kros, JM; Sillevis Smitt, PA; Spliet, WG; Teepen, JL; van den Bent, MJ; Wesseling, P, 2013) |
| " PCB was administered as an oral dosage of 450 mg on days 1-2 and a total dose of 300 mg on day 3." | 6.73 | Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. ( Boiardi, A; Botturi, A; Eoli, M; Falcone, C; Filippini, G; Fiumani, A; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A, 2008) |
| "Anaplastic oligodendrogliomas are more responsive to chemotherapy than high-grade astrocytomas." | 6.72 | Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer p ( Allgeier, A; Bernsen, HJ; Brandes, AA; Carpentier, AF; Frenay, M; Gorlia, T; Grisold, W; Haaxma-Reiche, H; Kros, JM; Lacombe, D; Sanson, M; Sipos, L; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ; van Kouwenhoven, MC; Vecht, CJ, 2006) |
| "Temozolomide was in general well tolerated; the most frequent side-effects were hematological." | 6.71 | Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. ( Baron, B; Boogerd, W; Bravo Marques, J; Chinot, O; De Beule, N; Kros, JM; Taphoorn, MJ; van den Bent, MJ; van der Rijt, CC; Vecht, CJ, 2003) |
| "NOA-18 aims at improving qualified overall survival (qOS) for adult patients with CNS WHO grade 2 and 3 oligodendrogliomas by randomizing between standard chemoradiation with up to six six-weekly cycles with PCV and six six-weekly cycles with lomustine and temozolomide (CETEG) (n = 182 patients per group accrued over 4 years) thereby delaying radiotherapy and adding the chemoradiotherapy concept at progression after initial radiation-free chemotherapy, allowing for effective salvage treatment and delaying potentially deleterious side effects." | 5.51 | Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial. ( Baumann, L; Bendszus, M; Combs, S; Dormann, A; Haut, T; Kessler, T; Kieser, M; Koch, M; Limprecht, R; Merkle-Lock, J; Pertz, M; Platten, M; Sahm, F; Sander, A; Schlegel, U; Selkrig, N; Walter, S; Wick, A; Wick, W; Winkler, F, 2022) |
| "Adding temozolomide (TMZ) to radiation for patients with newly-diagnosed anaplastic astrocytomas (AAs) is common clinical practice despite the lack of prospective studies demonstrating a survival advantage." | 5.22 | The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. ( Abuali, I; Grossman, SA; Lu, Y; Strowd, RE; Ye, X, 2016) |
| "To evaluate tumor responses, event-free survival (EFS), overall survival (OS), and toxicity of chemotherapy, children with neurofibromatosis type 1 (NF1) and progressive low-grade glioma were enrolled into the Children's Oncology Group (COG) A9952 protocol and treated with carboplatin and vincristine (CV)." | 5.22 | Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group. ( Ater, JL; Booth, TN; Freyer, DR; Mazewski, CM; Packer, RJ; Pollack, IF; Sposto, R; Vezina, G; Xia, C, 2016) |
| "Patients with anaplastic oligodendrogliomas (n = 288) who were randomized (EORTC 26951) to radiotherapy (RT) alone or RT plus procarbazine, lomustine, and vincristine (PCV) chemotherapy were analyzed." | 5.20 | Joint modeling of longitudinal health-related quality of life data and survival. ( Bottomley, A; Coens, C; Dirven, L; Ediebah, DE; Galindo-Garre, F; Reijneveld, JC; Ringash, J; Taphoorn, MJ; Uitdehaag, BM; van den Bent, MJ; Zikos, E, 2015) |
| "The addition of PCV (procarbazine, lomustine, and vincristine) chemotherapy to radiotherapy (RT) for patients with WHO grade 2 glioma improves progression-free survival (PFS)." | 5.19 | Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02. ( Barger, GR; Brachman, DG; Brown, PD; Buckner, JC; Gilbert, MR; Hu, C; Mehta, MP; Prabhu, RS; Shaw, EG; Stelzer, KJ; Won, M, 2014) |
| "The purpose of this prospective phase II/III trial was to study the effect of therapy intensification when combining procarbazine, lomustine, and vincristine (PCV) chemotherapy with a standard course of radiation therapy (RT) on cognitive functioning for patients with World Health Organization grade 2 low-grade gliomas (LGGs)." | 5.19 | Patients with primary brain tumors. ( Behrend, SW, 2014) |
| "Thalidomide and procarbazine have demonstrated single agent activity against malignant gliomas (MG)." | 5.16 | A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas. ( Case, D; Ellis, TL; Enevold, G; Lesser, GJ; McMullen, KP; McQuellon, RP; Rosdhal, R; Ruiz, J; Shaw, EG; Stieber, VW; Tatter, SB, 2012) |
| "Thirteen patients with temozolomide-refractory anaplastic oligodendroglioma (11 patients) or oligoastrocytoma (2 patients) underwent blood-brain barrier disruption with carboplatin (IA, 200 mg/m(2)/d), etoposide phosphate (IV, 200 mg/m(2)/d), and melphalan (IA, dose escalation) every 4 weeks, for up to 1 year." | 5.14 | Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study. ( Delashaw, JB; Doolittle, ND; Gahramanov, S; Guillaume, DJ; Hedrick, NA; Neuwelt, EA, 2010) |
| " We determined the effect of IDH1 mutations on progression-free survival and overall survival (OS), and its correlation with other clinical and molecular features in the prospective randomized European Organization for Research and Treatment of Cancer study 26951 on adjuvant procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea, and vincristine (PCV) in anaplastic oligodendroglioma." | 5.14 | IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. ( Brandes, AA; Dinjens, WN; Dubbink, HJ; Frenay, M; Gorlia, T; Idbaih, A; Kros, JM; Lacombe, D; Marie, Y; Sanson, M; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ; van Marion, R; Wesseling, P, 2010) |
| "The authors administered procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, lomustine), and vincristine (PCV) to 86 patients with recurrent glioblastoma." | 5.12 | PCV chemotherapy for recurrent glioblastoma. ( Dichgans, J; Dietz, K; Fischer, J; Herrlinger, U; Schmidt, F; Weller, M, 2006) |
| "We previously reported a phase 2 trial of 69 patients with newly diagnosed anaplastic or aggressive oligodendroglioma who were treated with intensive procarbazine, CCNU (lomustine), and vincristine (PCV) followed by high-dose thiotepa with autologous stem cell rescue." | 5.12 | High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. ( Abrey, LE; Bayer, R; Cairncross, JG; Childs, BH; DeAngelis, LM; Finlay, JL; Forsyth, P; Gardner, S; Hu, W; Kaminer, L; Macdonald, DR; Nimer, SD; Paleologos, N; Peterson, K; Ramsay, DA; Rosenfeld, S; Salzman, D; Smith, AM; Stewart, D; Swinnen, L; Weaver, S, 2006) |
| "Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are treated with surgery and radiotherapy (RT) at diagnosis, but they also respond to procarbazine, lomustine, and vincristine (PCV), raising the possibility that early chemotherapy will improve survival." | 5.12 | Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. ( Berkey, B; Brachman, D; Buckner, J; Cairncross, G; Curran, W; Fink, K; Jenkins, R; Laperierre, N; Mehta, M; Scheithauer, B; Shaw, E; Souhami, L, 2006) |
| "To evaluate the feasibility of 1-(4-amino- 2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) of pre-treated procarbazine for elderly patients with newly diagnosed glioblastomas." | 5.12 | Feasibility and response to 1-(4-amino-2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride chemotherapy with pre-treated procarbazine for elderly patients with newly diagnosed glioblastoma. ( Abe, T; Miyagi, N; Ogo, E; Shigemori, M; Terasaki, M, 2007) |
| "Twenty-three patients with recurrent or progressive oligodendrogliomas or oligoastrocytomas after first-line PCV (procarbazine, lomustine, and vincristine) chemotherapy were enrolled in a single-institution Phase II study of second-line carboplatin chemotherapy." | 5.11 | Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study. ( Borgognone, M; Costanza, A; Laguzzi, E; Mutani, R; Nobile, M; Rudà, R; Soffietti, R, 2004) |
| " The group is now preparing a multi-institutional randomized controlled phase II/III study of chemoradiotherapy using ACNU versus procarbazine and ACNU for astrocytoma grades 3 and 4." | 5.11 | Randomized controlled trial on malignant brain tumors--activities of the Japan Clinical Oncology Group-Brain Tumor Study Group. ( Shibui, S, 2004) |
| "The authors investigated the results of PCV chemotherapy within a cohort of 24 patients treated within the EORTC study 26971 on temozolomide chemotherapy in recurrent oligodendroglioma." | 5.11 | Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. ( Allgeier, A; Brandes, AA; Enting, RH; Frenay, M; Kros, JM; Menten, J; Stege, EB; Taphoorn, MJ; Tosoni, A; Triebels, VH; van den Bent, MJ; van Heuvel, I, 2004) |
| "Temozolomide (TMZ) is an oral alkylating agent with a good safety profile and proven efficacy in the treatment of malignant glioma." | 5.10 | Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. ( Foster, T; Newlands, ES; Zaknoen, S, 2003) |
| "The aim of this study was to compare tolerance of a nitrosurea-based regime with 'standard' therapy of vincristine (VCR) and carboplatin for low-grade gliomas." | 5.10 | Tolerance of nitrosurea-based multiagent chemotherapy regime for low-grade pediatric gliomas. ( Hoddes, JA; Lancaster, DL; Michalski, A, 2003) |
| "To conduct a Phase II study to evaluate the long-term efficacy and safety of high-dose 5'-bromodeoxyuridine (BrdU) and accelerated radiotherapy followed by procarbazine, lomustine (CCNU), and vincristine (PCV) chemotherapy in patients with glioblastoma multiforme." | 5.09 | A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. ( Bruner, JM; Groves, MD; Hess, K; Jaeckle, KA; Kyritsis, AP; Levin, VA; Maor, MH; Meyers, C; Peterson, P; Sawaya, RE; Yung, WK, 1999) |
| "To determine whether chemotherapy with temozolomide (TMZ) versus procarbazine (PCB) for recurrent glioblastoma multiforme (GBM) was associated with improvement in health-related quality of life (HRQOL)." | 5.09 | Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. ( Brada, M; Osoba, D; Prados, M; Yung, WK, 2000) |
| " Here we report our experience with adjuvant postirradiation and preirradiation chemotherapy using procarbazine, lomustine, and vincristine (PCV) in 27 patients with WHO grade II or III oligodendroglioma or oligoastrocytoma." | 5.09 | A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. ( Bamberg, M; Dichgans, J; Grote, EH; Meyermann, R; Schabet, M; Streffer, J; Voigt, K; Weller, M, 2000) |
| "A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse." | 5.09 | A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. ( Albright, RE; Brada, M; Bruner, J; Fink, K; Fredericks, R; Friedman, H; Glantz, M; Greenberg, H; Hohl, RJ; Levin, VA; Olson, J; Osoba, D; Phillips, P; Prados, MD; Rampling, R; Selker, RG; Shapiro, W; Spence, A; Vick, NA; Yue, N; Yung, WK; Zaknoen, S, 2000) |
| "Although the efficacy of the nitrosourea-based combination chemotherapy procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, and vincristine (PCV) has been previously demonstrated in the setting of anaplastic/intermediate-grade gliomas, the benefit for glioblastoma patients remains unproven." | 5.09 | Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. ( Bruner, JM; Chang, SM; Choucair, A; Flynn, PJ; Gleason, MJ; Hess, KR; Jaeckle, KA; Kyritsis, AP; Levin, VA; Prados, MD; Uhm, JH, 2000) |
| "The aims of this phase I study in patients with recurrent malignant gliomas were to determine the maximum tolerated dose (MTD) and toxicity profile of fotemustine when combined with a fixed dose of procarbazine (PCZ), and to evaluate the extent of O6-alkylguanine-DNA alkyltransferase (ATase) depletion in circulating lymphocytes during treatment." | 5.09 | Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte 06-alkylguanine-DNA alkyltransferase activity. ( Berger, E; Boiardi, A; Ciusani, E; Giroux, B; Lucas, C; Margison, G; Silvani, A; Watson, A, 2001) |
| "To conduct a Phase II one-arm study to evaluate the long-term efficacy and safety of accelerated fractionated radiotherapy combined with intravenous carboplatin for patients with previously untreated glioblastoma multiforme tumors." | 5.08 | Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. ( Bruner, J; Kyritsis, AP; Leeds, N; Levin, VA; Maor, MH; Rodriguez, L; Sawaya, R; Thall, PF; Woo, S; Yung, WK, 1995) |
| "A prospective phase II study of paclitaxel was performed in adult patients with recurrent hemispheric oligodendrogliomas." | 5.08 | Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. ( Chamberlain, MC; Kormanik, PA, 1997) |
| "Twenty six (17 males) patients with glioblastoma (GBL), median age 55 years, median Karnofsky Index (KI) 70/100, and 11 patients (9 males) with anaplastic astrocytoma (AA), median age 56 years, median KI 70/100 were treated at recurrence with dibromodulcitol (DBD) 1400 mg/m2 on day 1, BCNU 150 mg/m2 on day 2, and procarbazine (PCZ) 150 mg/day on days 1 to 15." | 5.08 | Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine--a phase-II study. ( De Witte, O; Hildebrand, J; Sahmoud, T, 1998) |
| "Previous investigators have reported responses in 52% of patients treated with mechlorethamine (nitrogen mustard), vincristine, and procarbazine (MOP) for recurrent glioma." | 5.08 | Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results. ( Buckner, JC; Burch, PA; Dinapoli, RP; Galanis, E; Mailliard, JA; Morton, RF; Novotny, PJ; Rowland, KM; Schaefer, PL; Scheithauer, BW; Vukov, AM, 1998) |
| "The regimen of procarbazine, CCNU, and vincristine is active against gliomas." | 5.08 | Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas. ( Cornetta, K; Dropcho, E; Heilman, DK; Jakacki, RI; Jamison, C; Macdonald, DR; Mathews, VP; Williams, DA, 1998) |
| "To examine the rate and duration of response of anaplastic oligodendrogliomas to a dose-escalated combination chemotherapy regimen consisting of procarbazine, lomustine (CCNU), and vincristine (PCV) and to evaluate the side effects of this treatment." | 5.07 | Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. ( Buckner, J; Cairncross, G; Cascino, T; Dropcho, E; Fulton, D; Lee, D; Ludwin, S; Macdonald, D; Schold, C; Stewart, D, 1994) |
| "In a study activated in 1983 and closed in 1987, the Brain Tumor Research Center of the University of California and the Northern California Cancer Center evaluated the effect of bromodeoxyuridine in the treatment of glioblastoma multiforme." | 5.07 | Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study. ( Ahn, DK; Davis, RL; Flam, MS; Gutin, PH; Levin, VA; Phillips, TL; Prados, MD; Wara, WM; Wilson, CB, 1991) |
| " The protocol called for a randomized trial that compared the effects of following 60 Gy radiation/oral hydroxyurea treatment with either carmustine (BCNU) or the combination of procarbazine, lomustine (CCNU), and vincristine (PCV) for two histologic strata: glioblastoma multiforme and other anaplastic gliomas." | 5.06 | Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. ( Davis, RL; Gutin, PH; Hannigan, J; Levin, VA; Silver, P; Wara, WM; Wilson, CB, 1990) |
| "The majority of patients with high-risk lower grade gliomas (LGG) are treated with single-agent temozolomide (TMZ) and radiotherapy despite three randomized trials showing a striking overall survival benefit with adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy and radiotherapy." | 5.05 | Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. ( Atkins, KM; Dietrich, J; Loeffler, JS; McDuff, SGR; Oh, KS; Shih, HA, 2020) |
| "Within 3 weeks of definitive surgery, 609 patients with histologically demonstrated, supratentorial malignant glioma were randomized to receive, in addition to 6000 rads of radiotherapy, one of four treatment regimens: carmustine (BCNU), high-dose methylprednisolone, procarbazine, or BCNU plus high-dose methylprednisolone." | 5.05 | Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. ( Alexander, E; Batzdorf, U; Brooks, WH; Byar, DP; Green, SB; Hunt, WE; Mealey, J; Odom, GL; Paoletti, P; Pistenmaa, DA; Ransohoff, J; Robertson, JT; Selker, RG; Shapiro, WR; Smith, KR; Strike, TA; Walker, MD; Wilson, CB, 1983) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 4.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| "Anaplastic oligodendrogliomas (AOs) are rare brain tumors responsive to chemotherapy with procarbazine, lomustine (CCNU) and vincristine (PCV), especially when harboring 1p19q codeletion." | 4.91 | Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen? ( Lassman, AB, 2015) |
| "The long-term follow-up of the RTOG 9802 trial that compared 54 Gy of radiotherapy (RT) with the same RT followed by adjuvant procarbazine, CCNU, and vincristine (PCV) chemotherapy in high-risk low-grade glioma shows a major increase in survival after adjuvant PCV chemotherapy." | 4.90 | Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma. ( van den Bent, MJ, 2014) |
| "The methylhydrazine derivative Procarbazine (PCZ) as monotherapy or in combination with CCNU and vincristine (PCV) was evaluated in a vast number of clinical trials and is still used in patients with high-grade and low-grade gliomas." | 4.84 | Procarbazine--a traditional drug in the treatment of malignant gliomas. ( Bogdahn, U; Goerne, R; Hau, P, 2008) |
| " In this paper we address different clinical outcomes measures separately and we illustrate the value of multiple outcome measures using the results of a recent clinical trial comparing temozolomide with procarbazine in the treatment of Glioblastoma Multiforme." | 4.82 | Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. ( Kiebert, G; Macdonald, DR; Olson, J; Prados, M; Yung, A, 2005) |
| "We report two patients with acute myeloid leukemia (AML) following therapy for malignant glioma; one was a young women treated heavily with alkylating agents for glioblastoma and the other a young man treated with high doses of procarbazine, lomustine, and vincristine (PCV) for anaplastic astrocytoma." | 4.80 | Acute leukemia following treatment of malignant glioma. ( Brown, MT; Gockerman, JP; Perry, JR, 1998) |
| "The authors report the clinical features of hypersensitivity reactions believed to result from procarbazine in eight patients treated with mechlorethamine, vincristine, and procarbazine (MOP) for high-grade glioma." | 4.78 | Hypersensitivity reactions to procarbazine with mechlorethamine, vincristine, and procarbazine chemotherapy in the treatment of glioma. ( Bushunow, P; Coyle, T; Graziano, S; Winfield, J; Wright, J, 1992) |
| " Here we describe the occurrence of pseudoprogression in patients with anaplastic oligodendrogliomas treated with postoperative procarbazine, lomustine and vincristine (PCV) chemotherapy alone." | 4.31 | T2-Fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone. ( Boutet, C; Carpentier, C; Dehais, C; Di Stefano, AL; Ducray, F; Esparragosa Vazquez, I; Figarella-Branger, D; Forest, F; Larrieu-Ciron, D; Meyronet, D; Ndiaye, M; Picart, T; Rivoirard, R; Seyve, A; Vassal, F; Younan, N, 2023) |
| "IDH-mutant anaplastic astrocytomas (AAs) are chemosensitive tumors for which the best choice of adjuvant chemotherapy between procarbazine, lomustine, and vincristine (PCV) or temozolomide (TMZ) after radiotherapy (RT) remains unclear." | 4.02 | Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort. ( Bronniman, C; Carpentier, C; Ciron, DL; Dehais, C; Ducray, F; Esteyrie, V; Figarella-Branger, D; Martin, E; Moyal, EC; Network, P; Pouessel, D; Uro-Coste, E, 2021) |
| "Following optimal local therapy, adjuvant Procarbazine, Lomustine and Vincristine (PCV) improves overall survival (OS) in low-grade glioma (LGG)." | 4.02 | One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre. ( Aslam, R; Breathnach, OS; Coyne, Z; Grogan, L; Hennessy, BT; Hennessy, MA; Keogh, RJ; Morris, PG, 2021) |
| "Patients (n = 142) with molecularly defined oligodendroglioma (WHO 2016) were assigned to four cohorts: W&S, wait-and-scan after stereotactic biopsy (n = 59); RES, surgical resection only (n = 27); TMZ, temozolomide after biopsy (n = 26) or PCV (n = 30) after biopsy." | 4.02 | PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression. ( Egensperger, R; Karschnia, P; Katzendobler, S; Lietke, S; Suchorska, B; Thon, N; Tonn, JC; Weller, J; Weller, M, 2021) |
| "Systematic evaluation of the effectiveness and safety of combined procarbazine, lomustine, and vincristine for treating recurrent high-grade glioma." | 3.96 | A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis. ( Cai, Y; Jiang, YG; Jiang, ZH; Tan, ZG; Wang, M, 2020) |
| " However, a randomized controlled study (RTOG 9802) showed that adding of procarbazine, CCNU, and vincristine (PCV) chemotherapy to fractionated radiotherapy (FRT) in patients with "high-risk" WHO grade II gliomas, including DA, has significant positive impact on both progression-free survival and overall survival." | 3.88 | Chemotherapy of Diffuse Astrocytoma (WHO grade II) in Adults. ( Narita, Y, 2018) |
| "Radiotherapy with procarbazine, lomustine, and vincristine (PCV) improves overall survival in patients with anaplastic oligodendroglioma 1p19q codeleted." | 3.88 | Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted. ( Castro-Martinez, E; Gonzalez-Aguilar, A; Guerrero-Juarez, V; Gutierrez-Aceves, A; Hernandez-Hernandez, A; Lopez-Martinez, M; Peiro-Osuna, RP; Reyes-Moreno, I; Santos-Zambrano, J, 2018) |
| "The addition of procarbazine, lomustine, vincristine (PCV) chemotherapy to radiotherapy (RT) for patients with high-risk (≥40 y old or subtotally resected) low-grade glioma (LGG) results in an absolute median survival benefit of over 5 years." | 3.85 | Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma. ( Bendavid, E; Chang, DT; Chin, AL; Durkee, BY; Harris, JP; Kim, H; Kumar, KA; Maruyama, S; Owens, DK; Pitt, A; Pollom, EL; Qian, Y; Soltys, SG, 2017) |
| "While procarbazine with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (PC) added to vincristine (PCV) was proven beneficial in the treatment of co-deleted anaplastic oligodendroglioma (AO), the question of whether PC alone is sufficient is important, as vincristine adds toxicity with uncertain benefit." | 3.81 | PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine. ( De Groot, J; Liu, D; Shonka, N; Smith, L; Webre, C, 2015) |
| "We previously developed a mathematical model capturing tumor size dynamics of adult low-grade gliomas (LGGs) before and after treatment either with PCV (Procarbazine, CCNU, and Vincristine) chemotherapy alone or with radiotherapy (RT) alone." | 3.81 | Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation. ( Ducray, F; Honnorat, J; Mazzocco, P; Ribba, B, 2015) |
| " This has changed with the long-term follow-up analysis of the EORTC and RTOG trials on procarbazine, lomustine, and vincristine (PCV) chemotherapy in anaplastic oligodendroglioma." | 3.79 | How to use molecular markers when caring for a patient with brain cancer: 1P/19Q as a predictive and prognostic marker in the neuro-oncology clinic. ( van den Bent, MJ, 2013) |
| " Among these tumors, a high percentage of low-grade oligodendrogliomas (ODG) are sensitive to chemotherapy with procarbazine, CCNU, and vincristine (PCV)." | 3.73 | Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. ( Branle, F; De Witte, O; Goldman, S; Sadeghi, N; Tang, BN; Wikler, D, 2005) |
| "We have reported that carmustine (BCNU) and cisplatin administered before, during, and after radiotherapy did not improve the survival of patients with high-grade astrocytomas and were associated with more serious toxicities than radiotherapy plus BCNU." | 3.73 | Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma. ( Jung, SM; Liau, CT; Tseng, CK; Wei, KC, 2005) |
| "We report the long-term follow-up, 71 months, of seven patients treated by procarbazine, lomustine and vincristine (PCV) therapy for a symptomatic low-grade oligodendrogliomatous tumor." | 3.73 | [Long-term outcome in patients with symptomatic low-grade oligodendrogliomatous tumors treated by cytotoxic agents]. ( Cartalat-Carel, S; Catenoix, H; Chapuis, F; Honnorat, J; Nighoghossian, N; Trouillas, P, 2006) |
| "We collected 6 case-reports of symptomatric non removable low grade fibrillary astrocytoma of adults treated with a procarbazine-CCNU-vincristine chemotherapy regimen." | 3.72 | [Neoadjuvant chemotherapy for symptomatic non operable grade II fibrillary astrocytoma in adults]. ( Alchaar, H; Bleuse, A; Bondiau, PY; Bourg, V; Brunetto, JL; Chanalet, S; Chatel, M; Courdi, A; Darcourt, J; Fauchon, F; Fontaine, D; Frénay, M; Grellier, P; Guibert, F; Lanteri-Minet, M; Lebrun, C; Lonjon, M; Michiels, JF; Paquis, P; Paquis, V; Ramaioli, A; Rasendrarijao, D; Vandenbos, F, 2004) |
| "To assess the feasibility and the activity, as well as the efficacy to treat meninges, of chemotherapy (CHT) containing high-dose methotrexate (HD-MTX) followed by radiation therapy (RT), without intrathecal CHT, in patients with primary central nervous system lymphoma." | 3.71 | Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients. ( Bernardi, M; Camba, L; Ciceri, F; Dell'Oro, S; Ferreri, AJ; Ponzoni, M; Reni, M; Spina, M; Terreni, MR; Tomirotti, M; Villa, E, 2001) |
| "We have studied the effects of medroxyprogesterone acetate (MPA) on C6 glioma growth in vitro in order to prove the hypothesis that it could arrest growth and induce drug sensitisation in a glial tumour as it does in breast cancer cells." | 3.71 | Medroxyprogesterone acetate alone or synergistic with chemotherapy suppresses colony formation and DNA synthesis in C6 glioma in vitro. ( Altinoz, MA; Bilir, A; Onar, FD; Ozar, E; Sav, A, 2001) |
| " In glioblastomas (histological grade 4, n = 257) the same chemotherapy was evaluated versus two cycles 4 weeks apart of 160 mg lomustine (CCNU) orally instead of BCNU, combined with vincristine and procarbazine (PCV) versus no chemotherapy." | 3.70 | A retrospective study of the value of chemotherapy as adjuvant therapy to surgery and radiotherapy in grade 3 and 4 gliomas. ( Gundersen, S; Lote, K; Watne, K, 1998) |
| "The authors reviewed the results of neoadjuvant (preradiation) procarbazine, CCNU, and vincristine chemotherapy for anaplastic oligodendrogliomas because, increasingly, chemotherapy is prescribed before radiation for oligodendroglial neoplasms." | 3.70 | Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. ( Cairncross, JG; Macdonald, DR; Paleologos, NA; Vick, NA, 1999) |
| "We treated 54 patients, newly diagnosed for glioblastoma, with systemic chemotherapy (carmustine (BCNU) 100 mg/m2 and cisplatin 90 mg/m2 every 6 weeks) and radiotherapy soon after surgery." | 3.70 | Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. ( Boiardi, A; Broggi, G; Eoli, M; Pozzi, A; Salmaggi, A; Silvani, A, 1999) |
| "The aim of this study was to examine the range of sensitivity of a panel of short-term cultures derived from different types of malignant childhood brain tumours including medulloblastoma, ependymoma and glioblastoma multiforme to three cytotoxic drugs, lomustine (CCNU), vincristine (VCR) and procarbazine (PCB)." | 3.70 | Chemosensitivity in childhood brain tumours in vitro: evidence of differential sensitivity to lomustine (CCNU) and vincristine. ( Darling, JL; Harding, B; Harkness, W; Hayward, R; Lewandowicz, GM; Thomas, DG, 2000) |
| "A case of successful combination chemotherapy using vincristine, procarbazine, VP-16 and prednisolone to treat an inoperable low grade astrocytoma is presented." | 3.70 | Successful combination chemotherapy (vincristine, procarbazine, etoposide, and prednisolone) in the treatment of inoperable, radioresistant low grade astrocytoma: a case report. ( Janjindamai SHirunpat, S; Maipang MVasiknanonte, P, 2000) |
| "We report a patient who developed aplastic anemia after three courses of cyclohexylchloroethylnitrousurea (CCNU), procarbazine and oncovine administered after craniotomy and irradiation for brain astrocytoma." | 3.69 | Aplastic anemia induced by cyclohexylchloroethylnitrousurea. ( Elis, A; Lishner, M; Ravid, M; Savin, H, 1994) |
| "We administered chemotherapy in standard and intensified formulations of procarbazine, lomustine (CCNU), and vincristine to nine symptomatic patients with low-grade oligodendroglioma." | 3.69 | Low-grade oligodendroglioma responds to chemotherapy. ( DeAngelis, LM; Krol, GS; Mason, WP, 1996) |
| "Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy." | 3.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
| "Effective chemotherapy using PCV (procarbazine, lomustine and vincristine) has been documented in anaplastic oligodendrogliomas and oligoastrocytomas." | 3.69 | [Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma]. ( Bouffet, E; Bret, P; Helfre, S; Jouvet, A; Mertens, P; Mornex, F; Sindou, M; Thiesse, P, 1997) |
| "We compared sequential single-agent BCNU and procarbazine (PCB) chemotherapy in 31 patients with gliomas [grade IV (10), grade III (15), grade II (6)]." | 3.68 | Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas. ( Bromberg, J; Greenberg, HS; Junck, L; Newton, HB; Page, MA, 1993) |
| "Between 1978 and 1988, 20 children with medulloblastoma (MB) of the brain were treated postoperatively with MOPP (nitrogen mustard, vincristine, prednisone, and procarbazine)." | 3.68 | Therapy-related myelodysplastic syndrome in children with medulloblastoma following MOPP chemotherapy. ( Hayani, A; Mahoney, DH; Taylor, LD, 1992) |
| "Twenty-one patients with metastatic melanoma were treated synchronously with procarbazine and radiotherapy." | 3.67 | Effective palliation of melanoma with procarbazine and radiotherapy given by a low-dose fractionation schedule. ( Abbott, RL; Ahmad, A; Gill, PG; Zeicmanis, J, 1986) |
| "Twenty-six patients with intracerebral tumors (predominantly gliomas) were treated with intraarterial BCNU, VM-26, and cisplatin combined with the systemic administration of VM-26, methotrexate, vincristine, bleomycin, and procarbazine." | 3.67 | Combined intraarterial and systemic chemotherapy for intracerebral tumors. ( Benoit, B; Grahovac, Z; Hugenholtz, H; Richard, M; Russell, N; Stewart, DJ, 1987) |
| "Fourteen consecutive melanoma patients with evaluable metastatic disease were treated with combination chemotherapy including procarbazine, vincristine and lomustine (POC)." | 3.67 | Metastatic malignant melanoma treated with procarbazine, vincristine and lomustine (POC). ( Ardizzoni, A; Grimaldi, A; Repetto, L; Rosso, R; Sertoli, MR, 1987) |
| "One hundred and seventeen patients with cerebral glioma (Kernohan grades III and IV) were treated with adjuvant chemotherapy using procarbazine (PCB), CCNU and vincristine (VCR) following whole head irradiation." | 3.67 | Assay of anti-cancer drugs in tissue culture: relationship of relapse free interval (RFI) and in vitro chemosensitivity in patients with malignant cerebral glioma. ( Bozek, T; Capra, LG; Collins, CD; Darling, JL; Godlee, JN; Mooney, C; Mott, TJ; Paul, EA; Thomas, DG; Tobias, JS, 1985) |
| "A human medulloblastoma (BN-2) and a glioblastoma (BN-3) which were previously established in nude mice were used to determine the effect of combined modality therapy with gamma-radiation, and three chemotherapeutic agents, procarbazine, 1,4-cyclohexadiene-1,4-dicarbamic acid, 2,5-bis(1-aziridinyl)-3,6-dioxo diethylester (AZQ), and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)." | 3.66 | Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft model. ( Feola, J; Houchens, DP; Ovejera, AA; Slagel, DE, 1982) |
| "Twenty consecutive patients with supratentorial Grade III and IV astrocytomas were treated with postoperative radiotherapy, and a simultaneous induction chemotherapy with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), procarbazine, bleomycin, and maintenance chemotherapy with CCNU." | 3.66 | Radiotherapy combined with procarbazine, bleomycin, and CCNU in the treatment of high-grade supratentorial astrocytomas. ( Greiner, RH; Markwalder, H; Seiler, RW; Zimmerman, A, 1978) |
| "2 cases of recurrent medulloblastomas are described who both responded to vincristine alone and in combination with procarbazine." | 3.66 | Response to vincristine and Procarbazine of recurrent medulloblastomas. Report of 2 cases. ( Fricker, U; Reichenbach, W; Seiler, RW; Wagner, HP, 1978) |
| "Seventeen patients with recurrent medulloblastoma were treated with a combination of three drugs: procarbazine, CCNU, and vincristine (PCV)." | 3.66 | Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine. ( Crafts, DC; Edwards, MS; Levin, VA; Pischer, TL; Wilson, CB, 1978) |
| "Primary intraocular lymphoma is a rare variant of primary CNS lymphoma for which the optimum treatment strategy remains unknown." | 2.82 | Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma. ( Cheah, CY; Chihara, D; Dabaja, BS; Fowler, NH; Gombos, DS; Milgrom, S; Pinnix, CC, 2016) |
| "The prognosis of patients with anaplastic oligodendrogliomas (AOD) and oligoastrocytomas (AOA) is variable." | 2.78 | New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brai ( Bernsen, HJ; Brandes, AA; Delattre, JY; Frénay, M; Gorlia, T; Kouwenhoven, MC; Kros, JM; Lacombe, D; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ, 2013) |
| "Anaplastic oligodendroglioma are chemotherapy-sensitive tumors." | 2.78 | Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. ( Allgeier, A; Bernsen, HJ; Brandes, AA; Delattre, JY; Dinjens, WN; Enting, RH; Frenay, M; French, PJ; Gorlia, T; Grisold, W; Hoang-Xuan, K; Kouwenhoven, MC; Kros, JM; Lacombe, D; Sipos, L; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ; Vecht, CJ, 2013) |
| "Intrinsic subtypes are highly prognostic in EORTC 26951 and improve outcome prediction when combined with other prognostic factors." | 2.78 | Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC stu ( de Rooi, J; den Dunnen, WF; Eilers, PH; Erdem-Eraslan, L; French, PJ; Gorlia, T; Gravendeel, LA; Idbaih, A; Kros, JM; Sillevis Smitt, PA; Spliet, WG; Teepen, JL; van den Bent, MJ; Wesseling, P, 2013) |
| "RT alone for anaplastic oligodendroglioma." | 2.75 | Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. ( Brachman, D; Buckner, J; Cairncross, G; Curran, W; Fink, K; Jenkins, R; Laperriere, N; Mehta, M; Scheithauer, B; Shaw, E; Souhami, L; Wang, M, 2010) |
| "AOA tumors with necrosis are to be considered WHO grade IV tumors (GBM)." | 2.74 | Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. ( Allgeier, A; Brandes, AA; Bromberg, JE; Gorlia, T; Grisold, W; Ibdaih, A; Kouwenhoven, MC; Kros, JM; Lacombe, D; Mirimanoff, R; Mokhtari, K; Sipos, L; Teepen, JL; van den Bent, MJ; van Duinen, SG; Vandenbos, F; Vecht, CJ; Wesseling, P, 2009) |
| "Based on studies relating to anaplastic oligodendroglioma (OG) chemosensitivity and benefit of time to progression or overall survival, chemotherapy for pure OG has been proposed." | 2.73 | Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. ( Bourg, V; Chanalet, S; Fauchon, F; Fontaine, D; Frenay, M; Lebrun, C; Lonjon, M; Paquis, P; Ramaioli, A; Vandenbos, F, 2007) |
| " PCB was administered as an oral dosage of 450 mg on days 1-2 and a total dose of 300 mg on day 3." | 2.73 | Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. ( Boiardi, A; Botturi, A; Eoli, M; Falcone, C; Filippini, G; Fiumani, A; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A, 2008) |
| "Adult patients with anaplastic oligodendrogliomas received RT alone or RT plus PCV chemotherapy." | 2.73 | Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. ( Allgeier, A; Bernsen, HJ; Bottomley, A; Brandes, AA; Coens, C; Delattre, JY; Frénay, M; Lacombe, D; Mauer, ME; Sillevis Smitt, PA; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ, 2007) |
| "Anaplastic oligodendrogliomas are more responsive to chemotherapy than high-grade astrocytomas." | 2.72 | Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer p ( Allgeier, A; Bernsen, HJ; Brandes, AA; Carpentier, AF; Frenay, M; Gorlia, T; Grisold, W; Haaxma-Reiche, H; Kros, JM; Lacombe, D; Sanson, M; Sipos, L; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ; van Kouwenhoven, MC; Vecht, CJ, 2006) |
| "Temozolomide was in general well tolerated; the most frequent side-effects were hematological." | 2.71 | Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. ( Baron, B; Boogerd, W; Bravo Marques, J; Chinot, O; De Beule, N; Kros, JM; Taphoorn, MJ; van den Bent, MJ; van der Rijt, CC; Vecht, CJ, 2003) |
| "Anaplastic oligodendroglioma is a chemosensitive glial neoplasm." | 2.71 | High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma. ( Abrey, LE; Bayer, R; Cairncross, JG; Childs, BH; DeAngelis, LM; Finlay, JL; Forsyth, P; Gardner, S; Hu, W; Kaminer, L; Macdonald, DR; Nimer, SD; Paleologos, N; Peterson, K; Ramsey, DA; Rosenfeld, S; Salzman, D; Smith, AM; Stewart, D; Swinnen, L; Weaver, S, 2003) |
| "Because of the diffuse nature of gliomatosis cerebri (GC), surgery is not suitable, and large field radiotherapy carries the risk of severe toxicity." | 2.71 | Initial chemotherapy in gliomatosis cerebri. ( Carpentier, A; Cartalat-Carel, S; Chinot, O; Cougnard, J; Delattre, JY; Djafari, L; Duffau, H; Gervais, H; Hoang-Xuan, K; Honnorat, J; Laigle, F; Mokhtari, K; Napolitano, M; Sanson, M; Taillandier, L; Taillibert, S, 2004) |
| "Histologically, 69 had anaplastic astrocytoma; 14, anaplastic oligoastrocytoma; and 7, anaplastic oligodendroglioma." | 2.70 | Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. ( Bruner, J; Chang, E; Gleason, MJ; Hess, KR; Ictech, SA; Kyritsis, A; Leeds, N; Levin, VA; Maor, MH; Meyers, CA; Yung, WK, 2002) |
| "Estimated 4-year survival for the anaplastic astrocytoma (AA) stratum (n = 116) is 46%." | 2.68 | Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas. ( Davis, RL; Gutin, PH; Lamborn, K; Levin, VA; Phillips, TL; Prados, MR; Wara, WM; Wilson, CB, 1995) |
| "Seventy-nine patients harboring recurrent brain tumors received four cycles of infraophthalmic carotid injections of 160 mg of carmustine." | 2.67 | Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors. ( Hager, B; Hannisdal, E; Hirschberg, H; Nome, O; Watne, K, 1992) |
| "Those treated for glioblastoma multiforme had a mean Karnofsky Performance Score of 86% (range 60-100%) at 1 month and 75% (range 60-100%) at 24 months." | 2.67 | External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2. ( Gutin, PH; Larson, DA; Leibel, SA; Levin, VA; Phillips, TL; Prados, MD; Silver, P; Sneed, PK; Wara, WM; Weaver, KA, 1991) |
| "Seven children with previously treated brain tumors were enrolled in a phase I trial of 5-day continuous-infusion procarbazine at 360, 480, and 638 mg/m2/day." | 2.66 | Phase I trial of procarbazine as a 5-day continuous infusion in children with central nervous system tumors. ( Baram, T; Cangir, A; Pack, R; van Eys, J, 1987) |
| "Sixty-five patients with malignant brain tumors were treated with a combination of BCNU (100 mg/m2 qd X 1) and procarbazine (100 mg/m2 qd X 14); the cycle was repeated in 1 month and then on a 6-week schedule with procarbazine being given for 21 days." | 2.64 | BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors. ( Boldrey, EB; Crafts, DC; Elashoff, RM; Enot, KJ; Levin, VA; Pischer, TL; Schultz, MJ; Seager, M; Wilson, CB, 1976) |
| " On the other side, dosage and the interval between cycles of chemotherapy appear to be a determining factor in the activity, but the limits are very narrow." | 2.64 | [A study of the use of sequential chemotherapy in 176 cases of glioblastoma (author's transl)]. ( Buge, A; Poisson, M; Pouillart, P, 1978) |
| "Anaplastic oligodendrogliomas have long attracted interest because of their sensitivity to chemotherapy, in particular in the subset of 1p/19q co-deleted tumors." | 2.53 | Low-grade and anaplastic oligodendroglioma. ( Bromberg, JE; Buckner, J; Van Den Bent, MJ, 2016) |
| "Gliomas are the most frequent primary brain tumors." | 2.50 | [Management of gliomas]. ( Chapet, S; Lévy, S; Mazeron, JJ, 2014) |
| "Most malignant brain tumors are resistant to the chemotherapeutic agents because of the existence of several mechanisms or substances such as the blood-brain barrier, genes and proteins." | 2.43 | [Resent advances in chemotherapy for malignant brain tumors]. ( Shibui, S, 2005) |
| "The incidence of oligodendroglioma is increasing, most likely due to its improved recognition." | 2.42 | Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. ( Engelhard, HH; Mundt, A; Stelea, A, 2003) |
| "The diagnosis of gliomatosis cerebri with MR imaging remains difficult." | 2.42 | [Gliomatosis cerebri: report of 3 cases and review of recent literatures]. ( Arai, M; Kaizaki, Y; Kashihara, K; Kitamura, Y; Taguchi, M, 2003) |
| "Procarbazine was stopped after 2 cycles because of the development of a rash." | 2.42 | The role of PCV chemotherapy in the treatment of central neurocytoma: illustration of a case and review of the literature. ( Berger, MS; Chang, SM; Schmidt, MH; Uyehara-Lock, JH; von Koch, CS, 2003) |
| "Because oligodendroglioma are infiltrative tumors, the Mac Donald's response criteria, usually used for solid and contrast-enhanced tumors, seem not to be adapted." | 2.41 | PCV chemotherapy for oligodendroglioma: response analyzed on T2 weighted-MRI. ( Diabira, S; Gamelin, E; Jadaud, E; Menei, P; Rousselet, MC; Soulier, P, 2001) |
| "A case of primary intracerebral Hodgkin's disease (HD) without dural attachment in a 54-year-old immunocompetent patient is described." | 2.40 | Primary intracerebral Hodgkin's disease: report of a case with Epstein-Barr virus association and review of the literature. ( Bendszus, M; Klein, R; Kreipe, H; Müllges, W; Roggendorf, W; Woydt, M, 1999) |
| "Thoracic and abdominal irradiation for Hodgkin's disease was performed concomitantly with chemotherapy for the non-Hodgkin's lymphoma." | 2.38 | Cerebral non-Hodgkin's lymphoma discovered when treating Hodgkin's disease. ( Bergeron, C; Chatel, M; Darcel, F; Edan, C; Faivre, J; Jouan, H; Le Moine, P; Le Prise-Fleury, E; Patte, C; Tass, P, 1993) |
| "Procarbazine was not given as a specified protocol, but for patients who were ineligible or refused other protocols." | 2.38 | Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. ( Levin, VA; Prados, M; Rodriguez, LA; Silver, P, 1989) |
| "Temozolomide-based treatment was administered to 64 of 68 (94." | 1.72 | Early Postoperative Treatment versus Initial Observation in CNS WHO Grade 2 and 3 Oligodendroglioma: Clinical Outcomes and DNA Methylation Patterns. ( Aichholzer, M; Berghoff, AS; Dieckmann, K; Furtner, J; Goldberger, S; Hatziioannou, T; Heller, G; Leibetseder, A; Mair, MJ; Pichler, J; Preusser, M; Puhr, R; Tomasich, E; von Oertzen, T; Weis, S; Widhalm, G; Wöhrer, A, 2022) |
| "The study included 26 patients with anaplastic astrocytoma and 37 patients with glioblastoma; all patients were aged ≤18 years." | 1.43 | High-grade glioma in children and adolescents: a single-center experience. ( Akalan, N; Akyuz, C; Cengiz, M; Eren, G; Gurkaynak, M; Ozyigit, G; Varan, A; Yazici, G; Yüce, D; Zorlu, F, 2016) |
| "Ependymomas represent 10% of pediatric brain tumors." | 1.43 | [Pediatric ependymomas: Current diagnosis and therapy]. ( Alapetite, C; Beuriat, PA; Faure-Conter, C; Frappaz, D; Grill, J; Szathmari, A; Vasiljevic, A, 2016) |
| "Waldenström's macroglobulinemia (WM) is a neoplasm of lymphoplasmacytic cells that produces monoclonal IgM protein." | 1.42 | Successful Treatment of Bing-Neel Syndrome Accompanying Waldenström's Macroglobulinemia with R-MPV: A Case Report. ( Endo, S; Hata, H; Kawano, Y; Kikukawa, Y; Mitsuya, H; Miyagawa, E; Okuno, Y; Ueno, S; Yamamura-Fujimoto, A, 2015) |
| "Three scales, i." | 1.40 | Longitudinal quality of life data: a comparison of continuous and ordinal approaches. ( Albert, A; Bottomley, A; Coens, C; Donneau, AF; Mauer, M, 2014) |
| "Of the 13 children with a residual tumour, chemotherapy induced 2 partial responses (PR), 1 minor response (MR) and 1 stable disease (SD) with no recurrent disease." | 1.33 | High-grade glioma in children under 5 years of age: a chemotherapy only approach with the BBSFOP protocol. ( Chastagner, P; Doz, F; Dufour, C; Frappaz, D; Gentet, JC; Grill, J; Kalifa, C; Lellouch-Tubiana, A; Pichon, F; Plantaz, D; Puget, S; Raquin, MA, 2006) |
| "Epilepsy was the most important risk factor for disability." | 1.32 | Long-term sequelae in children treated for brain tumors: impairments, disability, and handicap. ( Jereb, B; Macedoni-Luksic, M; Todorovski, L, 2003) |
| "Procarbazine is a cytotoxic chemotherapeutic agent used in the treatment of lymphomas and brain tumors." | 1.32 | Determination of procarbazine in human plasma by liquid chromatography with electrospray ionization mass spectrometry. ( Batchelor, TT; Grossman, S; He, X; Supko, JG, 2004) |
| "Secondary anaplastic oligodendroglioma patients were younger than patients with de novo anaplastic oligodendrogliomas." | 1.32 | Long-term outcome of oligodendrogliomas. ( Bourg, V; Chanalet, S; Chatel, M; Fontaine, D; Frenay, M; Lebrun, C; Lonjon, M; Michiels, JF; Paquis, P; Ramaioli, A; Vandenbos, F, 2004) |
| "Infants and young children who have brain tumors have a poor rate of survival and high treatment associated morbidity." | 1.30 | MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children. ( Ater, JL; Bruner, J; Copeland, DR; Moore, B; van Eys, J; Woo, SY, 1997) |
| "Oligodendroglioma is a rare central nervous system tumor which may occur in pure or mixed histology." | 1.30 | Radiation and chemotherapy improve outcome in oligodendroglioma. ( Allison, RR; Barry, T; Schulsinger, A; Shin, KH; Vongtama, V, 1997) |
| " In addition, there was a significant dose-response association between the development of procarbazine hypersensitivity and the presence of therapeutic anticonvulsant serum levels (p = 0." | 1.30 | Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors. ( Coyle, TE; Hurteau, TE; Lehmann, DF; Newman, N, 1997) |
| "004), the elimination half-life was 35% shorter (12." | 1.30 | Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ( Joensuu, H; Kivistö, KT; Mäenpää, H; Neuvonen, PJ; Villikka, K, 1999) |
| "In human brain tumors, sensitivity to procarbazine as measured by sensitivity in a xenograft tumor model correlated inversely with amounts of the DNA repair enzyme O6-alkylguanine DNA alkyltransferase (AT)." | 1.29 | p53 mutations, O6-alkylguanine DNA alkyltransferase activity, and sensitivity to procarbazine in human brain tumors. ( Nisen, PD; Russell, SJ; Schold, SC; Shuford, M; Waber, PG; Ye, YW, 1995) |
| "Malignant oligodendrogliomas have been shown to be responsive to chemotherapy." | 1.28 | The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. ( Glass, J; Gruber, ML; Hochberg, FH; Louis, DN; Rattner, B; Smith, D, 1992) |
| "Six patients (1 anaplastic astrocytoma) have developed progressive disease." | 1.28 | VP-16, vincristine and procarbazine with radiation therapy for treatment of malignant brain tumors. ( Calogero, JA; Hellman, RM; Kaplan, BM, 1990) |
| "Procarbazine was ineffective." | 1.28 | The chemotherapeutic response of a murine (VM) model of human glioma. ( Bradford, R; Darling, JL; Thomas, DG, 1990) |
| " Toxic effects resulted when procarbazine, a drug of this class, was used in treating a child with a CNS tumor." | 1.28 | Monoamine oxidase inhibitor toxicity. ( Pack, R; Pfefferbaum, B; van Eys, J, 1989) |
| "Four who had nonirradiated anaplastic astrocytomas all responded and survived for 38+ to 48." | 1.27 | Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and systemic chemotherapy for malignant gliomas: a follow-up study. ( Avellanosa, AM; Barua, NR; Hong, CI; Patel, A; West, CR, 1983) |
| "12 patients with brain tumors were treated with a combination of procarbazine, CCNU (bis-2-chloroethyl-3-cyclohexyl-1-nitrosourea) and vincristine." | 1.27 | Procarbazine, CCNU and vincristine (PCV) combination chemotherapy for brain tumors. ( Biran, S; Brufman, G; Catane, R; Halpern, J; Sulkes, A, 1984) |
| " BCNU in combination with Vincristine and Procarbazine every 6 weeks." | 1.27 | Complications associated with intra-arterial BCNU administered in combination with vincristine and procarbazine for the treatment of malignant brain tumors. ( Balsys, R; Bremer, AM; Duarte, P; Gonzalez, N; Kleriga, E; Miller, RI; Nguyen, TQ; Northup, HM, 1984) |
| "Secondary acute leukemias are rare in the evolution of malignant gliomas and the usefulness of subsequent radiochemotherapy cannot be questioned at the present time." | 1.27 | Two cases of acute leukemia following treatment of malignant glioma. ( Audebert, AA; Canuel, C; Debray, J; Genot, JY; Krulik, M; Poisson, M; Renoux, M; Smadja, N; van Efferterre, R, 1983) |
| "The disease appeared to be a diffuse encephalopathy frequently affecting the higher cortical functions." | 1.27 | Neurologic dysfunction in patients treated for small cell carcinoma of the lung: a clinical and radiological study. ( Chak, LY; Cox, RS; Kushlan, PD; Porzig, KJ; Sikic, BI; Wasserstein, P; Zatz, LM, 1986) |
| "Malignant oligodendroglioma is a uniquely chemosensitive glial tumor." | 1.27 | Successful chemotherapy for recurrent malignant oligodendroglioma. ( Cairncross, JG; Macdonald, DR, 1988) |
| "Low median survival of patients with brain metastases (5." | 1.27 | [Clinical picture, diagnosis and treatment of the brain lesions in lymphosarcomas]. ( Kruglova, GV; Setdikov, RA, 1986) |
| "Central nervous system involvement with Hodgkin's disease is extremely rare and is almost always a late complication in patients who have widely disseminated disease in the usual nodal sites." | 1.27 | Hodgkin's disease presenting with isolated craniospinal involvement. ( Bender, BL; Mayernik, DG, 1986) |
| "Five children with brain tumors, who had had no prior chemotherapy, were treated with combination chemotherapy including nitrogen mustard, vincristine sulfate, procarbazine, prednisolone (MOPP) and intrathecal methotrexate." | 1.27 | [Combination chemotherapy with MOPP and intrathecal methotrexate in children with brain tumors]. ( Akita, H; Hashimoto, T; Hirose, M; Matsumoto, K; Miki, Y; Miyao, M; Ninomiya, T; Saijo, T; Sato, J, 1986) |
| "Intracranial hodgkin's disease, an extremely uncommon finding, is reported in a 21-year-old man." | 1.27 | Hodgkin's disease, intracranial involvement. Report of a case and review of the literature. ( Enriquez, R; Papac, R; Vera, R, 1985) |
| "Seven human brain tumors were transplanted into the brains (6/7 takes) and subcutaneous tissues (7/7 takes) of athymic nude mice." | 1.26 | Human brain tumor transplantation into nude mice. ( Basler, GA; Chernik, NL; Posner, JB; Shapiro, WR, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 94 (28.31) | 18.7374 |
| 1990's | 73 (21.99) | 18.2507 |
| 2000's | 96 (28.92) | 29.6817 |
| 2010's | 59 (17.77) | 24.3611 |
| 2020's | 10 (3.01) | 2.80 |
| Authors | Studies |
|---|---|
| Wick, A | 1 |
| Sander, A | 1 |
| Koch, M | 1 |
| Bendszus, M | 2 |
| Combs, S | 1 |
| Haut, T | 1 |
| Dormann, A | 1 |
| Walter, S | 1 |
| Pertz, M | 1 |
| Merkle-Lock, J | 1 |
| Selkrig, N | 1 |
| Limprecht, R | 1 |
| Baumann, L | 1 |
| Kieser, M | 1 |
| Sahm, F | 1 |
| Schlegel, U | 3 |
| Winkler, F | 2 |
| Platten, M | 1 |
| Wick, W | 5 |
| Kessler, T | 1 |
| Mair, MJ | 1 |
| Leibetseder, A | 1 |
| Heller, G | 1 |
| Puhr, R | 1 |
| Tomasich, E | 1 |
| Goldberger, S | 1 |
| Hatziioannou, T | 1 |
| Wöhrer, A | 1 |
| Widhalm, G | 1 |
| Dieckmann, K | 1 |
| Aichholzer, M | 1 |
| Weis, S | 1 |
| von Oertzen, T | 1 |
| Furtner, J | 1 |
| Pichler, J | 1 |
| Preusser, M | 1 |
| Berghoff, AS | 1 |
| Kaulen, LD | 1 |
| Baehring, JM | 1 |
| Esparragosa Vazquez, I | 1 |
| Ndiaye, M | 1 |
| Di Stefano, AL | 1 |
| Younan, N | 1 |
| Larrieu-Ciron, D | 1 |
| Seyve, A | 1 |
| Picart, T | 1 |
| Meyronet, D | 2 |
| Boutet, C | 1 |
| Vassal, F | 1 |
| Carpentier, C | 3 |
| Figarella-Branger, D | 2 |
| Dehais, C | 2 |
| Forest, F | 1 |
| Rivoirard, R | 1 |
| Ducray, F | 7 |
| McDuff, SGR | 1 |
| Dietrich, J | 1 |
| Atkins, KM | 1 |
| Oh, KS | 1 |
| Loeffler, JS | 2 |
| Shih, HA | 1 |
| Raswoli, M | 1 |
| Nobre, L | 1 |
| Hawkins, C | 1 |
| Bartels, UK | 1 |
| Tabori, U | 1 |
| Bouffet, E | 2 |
| Cai, Y | 1 |
| Jiang, YG | 1 |
| Wang, M | 4 |
| Jiang, ZH | 1 |
| Tan, ZG | 1 |
| Esteyrie, V | 1 |
| Martin, E | 1 |
| Uro-Coste, E | 1 |
| Bronniman, C | 1 |
| Pouessel, D | 1 |
| Ciron, DL | 1 |
| Moyal, EC | 1 |
| Network, P | 1 |
| Keogh, RJ | 1 |
| Aslam, R | 1 |
| Hennessy, MA | 1 |
| Coyne, Z | 1 |
| Hennessy, BT | 1 |
| Breathnach, OS | 1 |
| Grogan, L | 1 |
| Morris, PG | 1 |
| Weller, J | 1 |
| Katzendobler, S | 1 |
| Karschnia, P | 1 |
| Lietke, S | 1 |
| Egensperger, R | 1 |
| Thon, N | 1 |
| Weller, M | 8 |
| Suchorska, B | 1 |
| Tonn, JC | 1 |
| Qian, Y | 1 |
| Maruyama, S | 1 |
| Kim, H | 2 |
| Pollom, EL | 1 |
| Kumar, KA | 1 |
| Chin, AL | 1 |
| Harris, JP | 1 |
| Chang, DT | 1 |
| Pitt, A | 1 |
| Bendavid, E | 1 |
| Owens, DK | 1 |
| Durkee, BY | 1 |
| Soltys, SG | 1 |
| Parasramka, S | 1 |
| Talari, G | 1 |
| Rosenfeld, M | 1 |
| Guo, J | 1 |
| Villano, JL | 2 |
| Narita, Y | 2 |
| Gonzalez-Aguilar, A | 1 |
| Reyes-Moreno, I | 1 |
| Peiro-Osuna, RP | 1 |
| Hernandez-Hernandez, A | 1 |
| Gutierrez-Aceves, A | 1 |
| Santos-Zambrano, J | 1 |
| Guerrero-Juarez, V | 1 |
| Lopez-Martinez, M | 1 |
| Castro-Martinez, E | 1 |
| Wen, PY | 2 |
| Lee, EQ | 1 |
| Nayak, L | 1 |
| Reardon, DA | 1 |
| Rosenfeld, MR | 1 |
| van den Bent, MJ | 20 |
| Gorlia, T | 9 |
| Delattre, JY | 6 |
| Brandes, AA | 9 |
| Kros, JM | 15 |
| Taphoorn, MJ | 10 |
| Kouwenhoven, MC | 3 |
| Bernsen, HJ | 4 |
| Frénay, M | 10 |
| Tijssen, CC | 6 |
| Lacombe, D | 7 |
| Kim, YR | 1 |
| Kim, SH | 1 |
| Chang, JH | 1 |
| Suh, CO | 1 |
| Kim, SJ | 1 |
| Kim, Y | 1 |
| Hwang, DY | 1 |
| Jang, JE | 1 |
| Hyun, SY | 1 |
| Cheong, JW | 1 |
| Min, YH | 1 |
| Kim, JS | 1 |
| Roth, P | 2 |
| Aoki, H | 1 |
| Ogura, R | 1 |
| Tsukamoto, Y | 1 |
| Okada, M | 1 |
| Natsumeda, M | 1 |
| Isogawa, M | 1 |
| Yoshida, S | 1 |
| Fujii, Y | 1 |
| Prabhu, RS | 1 |
| Won, M | 2 |
| Shaw, EG | 5 |
| Hu, C | 1 |
| Brachman, DG | 2 |
| Buckner, JC | 7 |
| Stelzer, KJ | 1 |
| Barger, GR | 2 |
| Brown, PD | 3 |
| Gilbert, MR | 3 |
| Mehta, MP | 3 |
| Cairncross, JG | 15 |
| Jenkins, RB | 2 |
| Giannini, C | 1 |
| Fink, KL | 1 |
| Souhami, L | 4 |
| Laperriere, NJ | 1 |
| Huse, JT | 1 |
| Curran, WJ | 4 |
| Behrend, SW | 1 |
| Donneau, AF | 1 |
| Mauer, M | 1 |
| Coens, C | 3 |
| Bottomley, A | 3 |
| Albert, A | 1 |
| Lévy, S | 1 |
| Chapet, S | 1 |
| Mazeron, JJ | 1 |
| Ediebah, DE | 1 |
| Galindo-Garre, F | 1 |
| Uitdehaag, BM | 2 |
| Ringash, J | 1 |
| Reijneveld, JC | 1 |
| Dirven, L | 1 |
| Zikos, E | 1 |
| Taal, W | 1 |
| van der Rijt, CC | 2 |
| Dinjens, WN | 4 |
| Sillevis Smitt, PA | 5 |
| Wertenbroek, AA | 1 |
| Bromberg, JE | 3 |
| van Heuvel, I | 3 |
| Dixit, S | 1 |
| Hingorani, M | 1 |
| Schiff, D | 2 |
| Levin, VA | 26 |
| Carvalho, BF | 1 |
| Fernandes, AC | 1 |
| Almeida, DS | 1 |
| Sampaio, LV | 1 |
| Costa, A | 1 |
| Caeiro, C | 1 |
| Osório, L | 1 |
| Castro, L | 1 |
| Linhares, P | 1 |
| Damasceno, M | 1 |
| Vaz, RC | 1 |
| Webre, C | 1 |
| Shonka, N | 1 |
| Smith, L | 1 |
| Liu, D | 1 |
| De Groot, J | 1 |
| Cheah, CY | 1 |
| Milgrom, S | 1 |
| Chihara, D | 1 |
| Gombos, DS | 1 |
| Pinnix, CC | 1 |
| Dabaja, BS | 1 |
| Fowler, NH | 1 |
| Kikukawa, Y | 1 |
| Yamamura-Fujimoto, A | 1 |
| Endo, S | 1 |
| Miyagawa, E | 1 |
| Kawano, Y | 1 |
| Ueno, S | 1 |
| Mitsuya, H | 1 |
| Hata, H | 1 |
| Okuno, Y | 1 |
| Lassman, AB | 2 |
| Yazici, G | 1 |
| Zorlu, F | 1 |
| Cengiz, M | 1 |
| Ozyigit, G | 1 |
| Eren, G | 1 |
| Yüce, D | 1 |
| Varan, A | 2 |
| Akyuz, C | 2 |
| Akalan, N | 2 |
| Gurkaynak, M | 1 |
| Strowd, RE | 1 |
| Abuali, I | 1 |
| Ye, X | 1 |
| Lu, Y | 1 |
| Grossman, SA | 1 |
| Mazzocco, P | 1 |
| Honnorat, J | 4 |
| Ribba, B | 1 |
| Buckner, J | 5 |
| Pugh, SL | 1 |
| Chakravarti, A | 1 |
| Coons, S | 1 |
| Ricci, P | 1 |
| Bullard, D | 1 |
| Stelzer, K | 1 |
| Brachman, D | 4 |
| Suh, JH | 1 |
| Schultz, CJ | 2 |
| Bahary, JP | 1 |
| Fisher, BJ | 3 |
| Murtha, AD | 1 |
| Bell, EH | 1 |
| Ater, JL | 3 |
| Xia, C | 1 |
| Mazewski, CM | 2 |
| Booth, TN | 2 |
| Freyer, DR | 2 |
| Packer, RJ | 2 |
| Sposto, R | 3 |
| Vezina, G | 2 |
| Pollack, IF | 2 |
| Gramatzki, D | 1 |
| Felsberg, J | 2 |
| Hofer, S | 1 |
| Rushing, EJ | 1 |
| Hentschel, B | 1 |
| Westphal, M | 1 |
| Krex, D | 1 |
| Simon, M | 1 |
| Schnell, O | 1 |
| Reifenberger, G | 2 |
| Combs, SE | 1 |
| Schmidt-Graf, F | 1 |
| Meyer, B | 1 |
| Frappaz, D | 5 |
| Vasiljevic, A | 1 |
| Beuriat, PA | 1 |
| Alapetite, C | 1 |
| Grill, J | 3 |
| Szathmari, A | 1 |
| Faure-Conter, C | 1 |
| Goerne, R | 1 |
| Bogdahn, U | 1 |
| Hau, P | 1 |
| Huang, F | 1 |
| Kavan, P | 1 |
| Guiot, MC | 1 |
| Markovic, Y | 1 |
| Roberge, D | 1 |
| Baumert, BG | 1 |
| Stupp, R | 1 |
| Glas, M | 1 |
| Rasch, K | 1 |
| Wiewrodt, D | 1 |
| Herrlinger, U | 2 |
| Ibdaih, A | 2 |
| Mokhtari, K | 5 |
| van Duinen, SG | 1 |
| Teepen, JL | 2 |
| Wesseling, P | 4 |
| Vandenbos, F | 4 |
| Grisold, W | 4 |
| Sipos, L | 3 |
| Mirimanoff, R | 1 |
| Vecht, CJ | 4 |
| Allgeier, A | 5 |
| Vesper, J | 1 |
| Graf, E | 1 |
| Wille, C | 1 |
| Tilgner, J | 1 |
| Trippel, M | 1 |
| Nikkhah, G | 1 |
| Ostertag, C | 1 |
| Nakamura, M | 1 |
| Shimada, K | 1 |
| Nakase, H | 1 |
| Konishi, N | 1 |
| Cairncross, G | 5 |
| Shaw, E | 3 |
| Jenkins, R | 4 |
| Scheithauer, B | 2 |
| Fink, K | 4 |
| Laperriere, N | 2 |
| Mehta, M | 4 |
| Curran, W | 4 |
| DeAngelis, LM | 7 |
| Dubbink, HJ | 2 |
| Sanson, M | 7 |
| van der Lee-Haarloo, CR | 1 |
| Hegi, M | 1 |
| Jeuken, JW | 1 |
| Hartmann, C | 1 |
| Engel, C | 1 |
| Stoffels, M | 1 |
| Stockhammer, F | 1 |
| Sabel, MC | 1 |
| Koeppen, S | 1 |
| Ketter, R | 1 |
| Meyermann, R | 2 |
| Rapp, M | 1 |
| Meisner, C | 1 |
| Kortmann, RD | 1 |
| Pietsch, T | 1 |
| Wiestler, OD | 1 |
| Ernemann, U | 1 |
| Bamberg, M | 2 |
| von Deimling, A | 1 |
| Guillaume, DJ | 1 |
| Doolittle, ND | 1 |
| Gahramanov, S | 1 |
| Hedrick, NA | 1 |
| Delashaw, JB | 1 |
| Neuwelt, EA | 5 |
| Marie, Y | 1 |
| Idbaih, A | 4 |
| van Marion, R | 1 |
| Agha, CA | 1 |
| Ibrahim, S | 1 |
| Hassan, A | 1 |
| Elias, DA | 1 |
| Fathallah-Shaykh, HM | 1 |
| Peyre, M | 1 |
| Cartalat-Carel, S | 3 |
| Ricard, D | 1 |
| Jouvet, A | 3 |
| Pallud, J | 1 |
| Guyotat, J | 2 |
| Jouanneau, E | 2 |
| Sunyach, MP | 2 |
| Ferreri, AJ | 2 |
| Verona, C | 1 |
| Politi, LS | 1 |
| Chiara, A | 1 |
| Perna, L | 1 |
| Villa, E | 2 |
| Reni, M | 2 |
| Pe'er, J | 1 |
| Rowe, JM | 1 |
| Frenkel, S | 1 |
| Dann, EJ | 1 |
| Kong, DS | 1 |
| Kim, ST | 1 |
| Lee, JI | 1 |
| Suh, YL | 1 |
| Lim, DH | 1 |
| Kim, WS | 1 |
| Kwon, KH | 1 |
| Park, K | 1 |
| Kim, JH | 1 |
| Nam, DH | 1 |
| Dalmasso, C | 1 |
| Kouwenhoven, M | 1 |
| Jeuken, J | 1 |
| French, P | 1 |
| Teepen, J | 1 |
| Broët, P | 1 |
| Delattre, O | 1 |
| van den Bent, M | 2 |
| Hoang-Xuan, K | 4 |
| Taphoorn, M | 1 |
| Ogawa, K | 2 |
| Ishiuchi, S | 1 |
| Inoue, O | 2 |
| Yoshii, Y | 2 |
| Saito, A | 2 |
| Watanabe, T | 1 |
| Iraha, S | 2 |
| Toita, T | 2 |
| Kakinohana, Y | 2 |
| Ariga, T | 1 |
| Kasuya, G | 1 |
| Murayama, S | 2 |
| Iwamoto, FM | 1 |
| Cloughesy, TF | 1 |
| Aldape, KD | 1 |
| Rivera, AL | 1 |
| Eichler, AF | 1 |
| Louis, DN | 4 |
| Paleologos, NA | 2 |
| Ashby, LS | 1 |
| Roldán, GB | 1 |
| Ligon, KL | 1 |
| Robins, HI | 1 |
| Rocque, BG | 1 |
| Chamberlain, MC | 6 |
| Mason, WP | 2 |
| Weaver, SA | 1 |
| Green, RM | 1 |
| Kamar, FG | 1 |
| Abrey, LE | 5 |
| Jhanwar, SC | 1 |
| Rosenblum, MK | 2 |
| Panageas, KS | 1 |
| Ruiz, J | 1 |
| Case, D | 1 |
| Enevold, G | 1 |
| Rosdhal, R | 1 |
| Tatter, SB | 1 |
| Ellis, TL | 1 |
| McQuellon, RP | 1 |
| McMullen, KP | 1 |
| Stieber, VW | 1 |
| Lesser, GJ | 2 |
| Zhou, T | 1 |
| Holmes, E | 2 |
| Lazarus, KH | 1 |
| Prados, M | 4 |
| Wisoff, JH | 2 |
| Kuhnhenn, J | 1 |
| Kowalski, T | 1 |
| Steenken, S | 1 |
| Ostermann, K | 1 |
| Viaccoz, A | 1 |
| Lekoubou, A | 1 |
| Printz, C | 1 |
| Enting, RH | 3 |
| French, PJ | 2 |
| Shibui, S | 3 |
| Mizusawa, J | 1 |
| Beppu, T | 1 |
| Ogasawara, K | 1 |
| Sawamura, Y | 1 |
| Kobayashi, H | 1 |
| Nishikawa, R | 1 |
| Mishima, K | 1 |
| Muragaki, Y | 1 |
| Maruyama, T | 1 |
| Kuratsu, J | 1 |
| Nakamura, H | 2 |
| Kochi, M | 2 |
| Minamida, Y | 1 |
| Yamaki, T | 1 |
| Kumabe, T | 1 |
| Tominaga, T | 1 |
| Kayama, T | 1 |
| Sakurada, K | 1 |
| Nagane, M | 1 |
| Kobayashi, K | 1 |
| Ito, T | 1 |
| Yazaki, T | 1 |
| Sasaki, H | 1 |
| Tanaka, K | 1 |
| Takahashi, H | 1 |
| Asai, A | 1 |
| Todo, T | 1 |
| Wakabayashi, T | 2 |
| Takahashi, J | 1 |
| Takano, S | 1 |
| Fujimaki, T | 1 |
| Sumi, M | 1 |
| Miyakita, Y | 1 |
| Nakazato, Y | 1 |
| Sato, A | 1 |
| Fukuda, H | 1 |
| Nomura, K | 2 |
| Erdem-Eraslan, L | 1 |
| Gravendeel, LA | 1 |
| de Rooi, J | 1 |
| Eilers, PH | 1 |
| Spliet, WG | 1 |
| den Dunnen, WF | 1 |
| Murphy, C | 1 |
| Pickles, T | 1 |
| Knowling, M | 1 |
| Thiesse, B | 1 |
| Zander, T | 1 |
| Nettekoven, W | 1 |
| Kraus, JA | 1 |
| Pels, H | 1 |
| Ko, YD | 1 |
| Vetter, H | 1 |
| Klockgether, T | 1 |
| Baker, MJ | 1 |
| Brem, S | 1 |
| Daniels, S | 1 |
| Sherman, B | 1 |
| Phuphanich, S | 1 |
| Seiferheld, W | 3 |
| Schold, SC | 6 |
| Fisher, B | 2 |
| Gesme, D | 1 |
| O'Fallon, JR | 1 |
| Hammack, JE | 1 |
| Stafford, S | 1 |
| Hawkins, R | 1 |
| Scheithauer, BW | 2 |
| Erickson, BJ | 1 |
| Levitt, R | 1 |
| Louis, E | 1 |
| Keime-Guibert, F | 1 |
| Macedoni-Luksic, M | 1 |
| Jereb, B | 1 |
| Todorovski, L | 1 |
| Looijenga, LH | 2 |
| Langenberg, K | 1 |
| Dinjens, W | 1 |
| Graveland, W | 1 |
| Uytdewilligen, L | 1 |
| Vos, MJ | 1 |
| Barkhof, F | 1 |
| Heimans, JJ | 3 |
| Baayen, HC | 1 |
| Boogerd, W | 3 |
| Castelijns, JA | 1 |
| Elkhuizen, PH | 1 |
| Postma, TJ | 2 |
| Chinot, O | 2 |
| Bravo Marques, J | 1 |
| De Beule, N | 1 |
| Baron, B | 1 |
| Pommier, P | 1 |
| Martel Lafay, I | 1 |
| Ginestet, G | 1 |
| Sindou, M | 2 |
| Bret, P | 2 |
| Carrie, C | 1 |
| Newlands, ES | 1 |
| Foster, T | 1 |
| Zaknoen, S | 2 |
| Lancaster, DL | 1 |
| Hoddes, JA | 1 |
| Michalski, A | 1 |
| Engelhard, HH | 1 |
| Stelea, A | 1 |
| Mundt, A | 1 |
| Khil'ko, VA | 1 |
| Khachatrian, VA | 1 |
| Shuleshova, NV | 1 |
| Arai, M | 1 |
| Kashihara, K | 1 |
| Kaizaki, Y | 1 |
| Taguchi, M | 1 |
| Kitamura, Y | 1 |
| von Koch, CS | 1 |
| Schmidt, MH | 1 |
| Uyehara-Lock, JH | 1 |
| Berger, MS | 1 |
| Chang, SM | 2 |
| He, X | 1 |
| Batchelor, TT | 1 |
| Grossman, S | 1 |
| Supko, JG | 1 |
| Lichy, MP | 1 |
| Bachert, P | 1 |
| Henze, M | 1 |
| Lichy, CM | 1 |
| Debus, J | 1 |
| Schlemmer, HP | 1 |
| Childs, BH | 2 |
| Paleologos, N | 4 |
| Kaminer, L | 3 |
| Rosenfeld, S | 3 |
| Salzman, D | 3 |
| Finlay, JL | 3 |
| Gardner, S | 2 |
| Peterson, K | 3 |
| Hu, W | 3 |
| Swinnen, L | 3 |
| Bayer, R | 3 |
| Forsyth, P | 4 |
| Stewart, D | 5 |
| Smith, AM | 2 |
| Macdonald, DR | 9 |
| Weaver, S | 2 |
| Ramsey, DA | 1 |
| Nimer, SD | 2 |
| Soffietti, R | 1 |
| Nobile, M | 1 |
| Rudà, R | 1 |
| Borgognone, M | 1 |
| Costanza, A | 1 |
| Laguzzi, E | 1 |
| Mutani, R | 1 |
| Lai, R | 1 |
| Prados, MD | 11 |
| Sandler, HM | 1 |
| Phillips, T | 2 |
| Schultz, C | 3 |
| Urtasun, R | 2 |
| Davis, R | 4 |
| Gutin, P | 3 |
| Cascino, TL | 2 |
| Greenberg, HS | 4 |
| Lebrun, C | 3 |
| Fontaine, D | 3 |
| Ramaioli, A | 3 |
| Chanalet, S | 3 |
| Lonjon, M | 3 |
| Michiels, JF | 2 |
| Bourg, V | 3 |
| Paquis, P | 3 |
| Chatel, M | 3 |
| Alchaar, H | 1 |
| Bleuse, A | 1 |
| Bondiau, PY | 1 |
| Brunetto, JL | 1 |
| Courdi, A | 1 |
| Darcourt, J | 1 |
| Fauchon, F | 2 |
| Guibert, F | 1 |
| Grellier, P | 1 |
| Lanteri-Minet, M | 1 |
| Paquis, V | 1 |
| Rasendrarijao, D | 1 |
| Taillibert, S | 1 |
| Napolitano, M | 1 |
| Djafari, L | 1 |
| Cougnard, J | 1 |
| Gervais, H | 1 |
| Laigle, F | 1 |
| Carpentier, A | 1 |
| Taillandier, L | 1 |
| Duffau, H | 1 |
| de Wit, MC | 1 |
| de Bruin, HG | 2 |
| Eijkenboom, W | 1 |
| Triebels, VH | 1 |
| Menten, J | 1 |
| Tosoni, A | 1 |
| Stege, EB | 1 |
| Teng, LH | 1 |
| Gui, QP | 1 |
| Xuan, Q | 1 |
| Lu, DH | 1 |
| Higuchi, Y | 1 |
| Iwadate, Y | 1 |
| Yamaura, A | 1 |
| Stege, EM | 1 |
| van der Rijt, CD | 1 |
| Smitt, PA | 1 |
| Tang, BN | 1 |
| Sadeghi, N | 1 |
| Branle, F | 1 |
| De Witte, O | 2 |
| Wikler, D | 1 |
| Goldman, S | 1 |
| Liau, CT | 1 |
| Wei, KC | 1 |
| Tseng, CK | 1 |
| Jung, SM | 1 |
| Kiebert, G | 1 |
| Yung, A | 1 |
| Olson, J | 2 |
| DeAngelis, L | 1 |
| Nelson, D | 1 |
| Neyns, B | 1 |
| Sadones, J | 1 |
| Chaskis, C | 1 |
| De Ridder, M | 1 |
| Keyaerts, M | 1 |
| Veld, PI | 1 |
| Michotte, A | 1 |
| Chintagumpala, MM | 1 |
| Friedman, HS | 3 |
| Stewart, CF | 1 |
| Kepner, J | 1 |
| McLendon, RE | 1 |
| Modrich, PL | 1 |
| McCluggage, C | 1 |
| Burger, P | 1 |
| Thompson, S | 1 |
| Rutka, J | 1 |
| Michalski, J | 1 |
| Woo, S | 2 |
| Blaney, SM | 1 |
| Kun, LE | 1 |
| Horowitz, ME | 2 |
| Ty, AU | 1 |
| See, SJ | 1 |
| Rao, JP | 1 |
| Khoo, JB | 1 |
| Wong, MC | 1 |
| Jones, R | 1 |
| Kirkup, M | 1 |
| Guglani, S | 1 |
| Hopkins, K | 1 |
| Schmidt, F | 1 |
| Fischer, J | 1 |
| Dietz, K | 1 |
| Dichgans, J | 3 |
| Ramsay, DA | 2 |
| Cornetta, K | 2 |
| Croop, J | 1 |
| Dropcho, E | 3 |
| Abonour, R | 1 |
| Kieran, MW | 1 |
| Kreissman, S | 1 |
| Reeves, L | 1 |
| Erickson, LC | 1 |
| Williams, DA | 2 |
| Walker, C | 2 |
| Haylock, B | 2 |
| Husband, D | 2 |
| Joyce, KA | 2 |
| Fildes, D | 2 |
| Jenkinson, MD | 2 |
| Smith, T | 2 |
| Broome, J | 2 |
| du Plessis, DG | 2 |
| Warnke, PC | 2 |
| Lang, FF | 1 |
| Berkey, B | 1 |
| Laperierre, N | 1 |
| Carpentier, AF | 1 |
| Haaxma-Reiche, H | 1 |
| van Kouwenhoven, MC | 1 |
| Partap, S | 1 |
| Spence, AM | 1 |
| Piccirilli, M | 1 |
| Landi, A | 1 |
| Salvati, M | 1 |
| Terasaki, M | 1 |
| Abe, T | 1 |
| Miyagi, N | 1 |
| Ogo, E | 1 |
| Shigemori, M | 1 |
| Adachi, G | 1 |
| Tamaki, W | 1 |
| Sugimoto, K | 1 |
| Hyodo, A | 1 |
| Dufour, C | 1 |
| Lellouch-Tubiana, A | 1 |
| Puget, S | 1 |
| Chastagner, P | 3 |
| Doz, F | 2 |
| Pichon, F | 1 |
| Plantaz, D | 1 |
| Gentet, JC | 2 |
| Raquin, MA | 2 |
| Kalifa, C | 2 |
| Kopitzki, K | 1 |
| Prosser, J | 1 |
| Vinjamuri, S | 1 |
| Atahan, L | 1 |
| Söylemezoglu, F | 1 |
| Selek, U | 1 |
| Yalçin, B | 1 |
| Kutluk, T | 1 |
| Büyükpamukçu, M | 1 |
| Catenoix, H | 1 |
| Chapuis, F | 1 |
| Nighoghossian, N | 1 |
| Trouillas, P | 1 |
| Yang, SH | 1 |
| Hong, YK | 1 |
| Yoon, SC | 1 |
| Kim, BS | 1 |
| Lee, YS | 1 |
| Lee, TK | 1 |
| Lee, KS | 1 |
| Jeun, SS | 1 |
| Kim, MC | 1 |
| Park, CK | 1 |
| Silvani, A | 3 |
| Lamperti, E | 1 |
| Gaviani, P | 1 |
| Eoli, M | 2 |
| Fiumani, A | 1 |
| Salmaggi, A | 2 |
| Falcone, C | 1 |
| Filippini, G | 1 |
| Botturi, A | 1 |
| Boiardi, A | 4 |
| Mauer, ME | 1 |
| Mohile, NA | 1 |
| Raizer, JJ | 1 |
| Kewalramani, T | 1 |
| Eyre, HJ | 2 |
| Quagliana, JM | 1 |
| Eltringham, JR | 2 |
| Frank, J | 1 |
| O'Bryan, RM | 1 |
| McDonald, B | 1 |
| Rivkin, SE | 1 |
| Hill, SA | 1 |
| Frenkel, EP | 1 |
| Seiler, RW | 3 |
| Moser, K | 1 |
| Pohl, A | 1 |
| Kelly, KA | 1 |
| Kirkwood, JM | 1 |
| Kapp, DS | 1 |
| Duffner, PK | 1 |
| Cohen, ME | 1 |
| Heffner, RR | 1 |
| Freeman, AI | 1 |
| Aisner, J | 1 |
| Whitacre, M | 1 |
| Van Echo, DA | 1 |
| Wiernik, PH | 1 |
| Lieberman, AN | 1 |
| Foo, SH | 1 |
| Ransohoff, J | 2 |
| Wise, A | 1 |
| George, A | 1 |
| Gordon, W | 1 |
| Walker, R | 1 |
| Bezwoda, WR | 1 |
| Derman, DP | 1 |
| de Moor, NG | 1 |
| Kallenbach, J | 1 |
| West, CR | 2 |
| Avellanosa, AM | 2 |
| Barua, NR | 1 |
| Patel, A | 1 |
| Hong, CI | 1 |
| Rana, SR | 1 |
| Haddy, TB | 1 |
| Ashayeri, E | 1 |
| Goldson, AL | 1 |
| Green, SB | 1 |
| Byar, DP | 1 |
| Walker, MD | 2 |
| Pistenmaa, DA | 1 |
| Alexander, E | 1 |
| Batzdorf, U | 1 |
| Brooks, WH | 1 |
| Hunt, WE | 1 |
| Mealey, J | 1 |
| Odom, GL | 1 |
| Paoletti, P | 1 |
| Robertson, JT | 1 |
| Selker, RG | 2 |
| Shapiro, WR | 7 |
| Smith, KR | 1 |
| Wilson, CB | 14 |
| Strike, TA | 1 |
| Greig, NH | 1 |
| Balaban, E | 1 |
| Diehl, J | 1 |
| Hill, S | 1 |
| Frenkel, E | 1 |
| Brufman, G | 1 |
| Halpern, J | 1 |
| Sulkes, A | 1 |
| Catane, R | 1 |
| Biran, S | 1 |
| Bremer, AM | 2 |
| Nguyen, TQ | 2 |
| Balsys, R | 2 |
| Kleriga, E | 1 |
| Northup, HM | 1 |
| Gonzalez, N | 1 |
| Duarte, P | 1 |
| Miller, RI | 1 |
| Cangir, A | 5 |
| Ragab, AH | 2 |
| Steuber, P | 1 |
| Land, VJ | 1 |
| Berry, DH | 2 |
| Krischer, JP | 1 |
| Schmitt, K | 1 |
| Tulzer, W | 1 |
| Bradley, NJ | 1 |
| Darling, JL | 5 |
| Oktar, N | 1 |
| Bloom, HJ | 2 |
| Thomas, DG | 4 |
| Davies, AJ | 1 |
| Rawlings, CE | 1 |
| Bigner, SH | 1 |
| Bigner, DD | 2 |
| Genot, JY | 1 |
| Krulik, M | 1 |
| Poisson, M | 3 |
| van Efferterre, R | 1 |
| Renoux, M | 1 |
| Audebert, AA | 1 |
| Canuel, C | 1 |
| Smadja, N | 1 |
| Debray, J | 1 |
| Vestnys, PS | 1 |
| Hildebrand, J | 2 |
| Slagel, DE | 1 |
| Feola, J | 1 |
| Houchens, DP | 1 |
| Ovejera, AA | 1 |
| Jellinger, K | 1 |
| Volc, D | 1 |
| Podreka, I | 1 |
| Flament, H | 1 |
| Vollmer, R | 1 |
| Weiss, R | 1 |
| Yung, WA | 1 |
| Basler, GA | 2 |
| Shapiro, JR | 2 |
| Eisenhauer, EA | 1 |
| Maor, MH | 3 |
| Thall, PF | 1 |
| Yung, WK | 9 |
| Bruner, J | 5 |
| Sawaya, R | 1 |
| Kyritsis, AP | 6 |
| Leeds, N | 2 |
| Rodriguez, L | 1 |
| Shrieve, DC | 1 |
| Coleman, CN | 1 |
| Sobol, RE | 1 |
| Fakhrai, H | 1 |
| Shawler, D | 1 |
| Gjerset, R | 1 |
| Dorigo, O | 1 |
| Carson, C | 1 |
| Khaleghi, T | 1 |
| Koziol, J | 1 |
| Shiftan, TA | 1 |
| Royston, I | 1 |
| Prados, MR | 1 |
| Wara, WM | 5 |
| Davis, RL | 4 |
| Gutin, PH | 6 |
| Phillips, TL | 4 |
| Lamborn, K | 4 |
| Röttinger, EM | 1 |
| Jeremic, B | 4 |
| Grujicic, D | 2 |
| Antunovic, V | 2 |
| Djuric, L | 2 |
| Stojanovic, M | 3 |
| Shibamoto, Y | 3 |
| Russell, SJ | 1 |
| Ye, YW | 1 |
| Waber, PG | 1 |
| Shuford, M | 1 |
| Nisen, PD | 1 |
| Fine, HA | 1 |
| Macdonald, D | 3 |
| Ludwin, S | 1 |
| Lee, D | 1 |
| Cascino, T | 1 |
| Fulton, D | 1 |
| Schold, C | 1 |
| Geyer, JR | 2 |
| Zeltzer, PM | 1 |
| Boyett, JM | 1 |
| Rorke, LB | 1 |
| Stanley, P | 1 |
| Albright, AL | 1 |
| Milstein, JM | 2 |
| Allen, JC | 1 |
| Elis, A | 1 |
| Lishner, M | 1 |
| Savin, H | 1 |
| Ravid, M | 1 |
| Watne, K | 4 |
| Hannisdal, E | 2 |
| Nome, O | 2 |
| Hager, B | 3 |
| Hirschberg, H | 2 |
| Newton, HB | 2 |
| Bromberg, J | 2 |
| Junck, L | 2 |
| Page, MA | 2 |
| Schuler, D | 3 |
| Somló, P | 2 |
| Koós, R | 2 |
| Kálmánchey, R | 1 |
| Paraicz, E | 2 |
| Bergeron, C | 1 |
| Le Moine, P | 1 |
| Le Prise-Fleury, E | 1 |
| Jouan, H | 1 |
| Tass, P | 1 |
| Darcel, F | 1 |
| Edan, C | 2 |
| Patte, C | 1 |
| Faivre, J | 1 |
| Krol, GS | 1 |
| Ilveskoski, I | 1 |
| Saarinen, UM | 1 |
| Wiklund, T | 1 |
| Perkkiö, M | 1 |
| Salmi, TT | 1 |
| Lanning, M | 1 |
| Mäkipernaa, A | 1 |
| Pihko, H | 1 |
| Forsyth, PA | 1 |
| Kim, L | 1 |
| Hochberg, FH | 2 |
| Thornton, AF | 1 |
| Harsh, GR | 1 |
| Patel, H | 1 |
| Finkelstein, D | 1 |
| Jaeckle, KA | 6 |
| Gleason, MJ | 3 |
| Ictech, SE | 1 |
| Flowers, A | 1 |
| Edwards, MS | 3 |
| Rabbitt, J | 2 |
| van Eys, J | 7 |
| Woo, SY | 1 |
| Moore, B | 1 |
| Copeland, DR | 1 |
| Kaba, SE | 1 |
| Hess, K | 2 |
| Mercier, R | 1 |
| Dakhil, S | 1 |
| Allison, RR | 1 |
| Schulsinger, A | 1 |
| Vongtama, V | 1 |
| Barry, T | 1 |
| Shin, KH | 1 |
| Lehmann, DF | 1 |
| Hurteau, TE | 1 |
| Newman, N | 1 |
| Coyle, TE | 1 |
| Wara, W | 3 |
| Ater, J | 1 |
| Rabbit, J | 1 |
| Kormanik, PA | 2 |
| Mornex, F | 1 |
| Thiesse, P | 1 |
| Mertens, P | 1 |
| Helfre, S | 1 |
| Sahmoud, T | 1 |
| van Groeningen, CJ | 2 |
| Witjes, RJ | 1 |
| Weerts, JG | 1 |
| Kralendonk, JH | 1 |
| Bauman, GS | 2 |
| Abele, M | 1 |
| Leonhardt, M | 1 |
| Galanis, E | 1 |
| Burch, PA | 1 |
| Schaefer, PL | 1 |
| Dinapoli, RP | 1 |
| Novotny, PJ | 1 |
| Rowland, KM | 1 |
| Vukov, AM | 1 |
| Mailliard, JA | 1 |
| Morton, RF | 1 |
| Pronk, LC | 1 |
| Krouwer, HG | 1 |
| Zonnenberg, BA | 1 |
| Twijnstra, A | 1 |
| Punt, CJ | 1 |
| Jakacki, RI | 1 |
| Jamison, C | 1 |
| Mathews, VP | 1 |
| Heilman, DK | 1 |
| Paál, K | 1 |
| Horváth, J | 1 |
| Csáki, C | 1 |
| Ferencz, T | 1 |
| Borsi, JD | 1 |
| Perry, JR | 1 |
| Brown, MT | 1 |
| Gockerman, JP | 1 |
| Gundersen, S | 1 |
| Lote, K | 1 |
| Ermani, M | 1 |
| Turazzi, S | 1 |
| Scelzi, E | 1 |
| Berti, F | 1 |
| Amistà, P | 1 |
| Rotilio, A | 1 |
| Licata, C | 1 |
| Fiorentino, MV | 1 |
| Klein, R | 1 |
| Müllges, W | 1 |
| Woydt, M | 1 |
| Kreipe, H | 1 |
| Roggendorf, W | 1 |
| Groves, MD | 1 |
| Meyers, C | 1 |
| Sawaya, RE | 1 |
| Bruner, JM | 3 |
| Peterson, P | 1 |
| Vick, NA | 2 |
| Gruijicic, D | 1 |
| Milicic, B | 1 |
| Nikolic, N | 1 |
| Dagovic, A | 1 |
| Aleksandrovic, J | 1 |
| Scott, C | 1 |
| Sandler, H | 1 |
| Villikka, K | 1 |
| Kivistö, KT | 1 |
| Mäenpää, H | 1 |
| Joensuu, H | 1 |
| Neuvonen, PJ | 1 |
| Osoba, D | 2 |
| Brada, M | 2 |
| Källén, K | 1 |
| Geijer, B | 1 |
| Malmström, P | 1 |
| Andersson, AM | 1 |
| Holtås, S | 1 |
| Ryding, E | 1 |
| Rosén, I | 1 |
| Streffer, J | 1 |
| Schabet, M | 1 |
| Grote, EH | 1 |
| Voigt, K | 1 |
| Pozzi, A | 1 |
| Broggi, G | 1 |
| Albright, RE | 1 |
| Fredericks, R | 1 |
| Spence, A | 1 |
| Hohl, RJ | 1 |
| Shapiro, W | 1 |
| Glantz, M | 1 |
| Greenberg, H | 1 |
| Rampling, R | 1 |
| Friedman, H | 1 |
| Phillips, P | 1 |
| Yue, N | 1 |
| Lewandowicz, GM | 1 |
| Harding, B | 1 |
| Harkness, W | 1 |
| Hayward, R | 1 |
| Uhm, JH | 1 |
| Choucair, A | 1 |
| Flynn, PJ | 1 |
| Hess, KR | 3 |
| Le Deley, MC | 1 |
| Gambarelli, D | 1 |
| Couanet, D | 1 |
| Pierre-Kahn, A | 1 |
| Habrand, JL | 1 |
| Dell'Oro, S | 1 |
| Ciceri, F | 1 |
| Bernardi, M | 1 |
| Camba, L | 1 |
| Ponzoni, M | 1 |
| Terreni, MR | 1 |
| Tomirotti, M | 1 |
| Spina, M | 1 |
| Maipang MVasiknanonte, P | 1 |
| Janjindamai SHirunpat, S | 1 |
| Edwards, M | 1 |
| Malec, M | 1 |
| Ramsay, D | 1 |
| Smith, A | 1 |
| Kajita, Y | 1 |
| Mizuno, M | 1 |
| Nagasaka, T | 1 |
| Yoshida, J | 1 |
| Ciusani, E | 1 |
| Watson, A | 1 |
| Margison, G | 1 |
| Berger, E | 1 |
| Lucas, C | 1 |
| Giroux, B | 1 |
| Wong, ET | 1 |
| Altinoz, MA | 1 |
| Bilir, A | 1 |
| Ozar, E | 1 |
| Onar, FD | 1 |
| Sav, A | 1 |
| Diabira, S | 1 |
| Rousselet, MC | 1 |
| Gamelin, E | 1 |
| Soulier, P | 1 |
| Jadaud, E | 1 |
| Menei, P | 1 |
| Kyritsis, A | 1 |
| Meyers, CA | 1 |
| Ictech, SA | 1 |
| Chang, E | 1 |
| Ushio, Y | 1 |
| Croteau, D | 1 |
| Mikkelsen, T | 1 |
| Greiner, RH | 1 |
| Zimmerman, A | 1 |
| Markwalder, H | 1 |
| Weiss, HD | 1 |
| Crafts, DC | 3 |
| Schultz, MJ | 1 |
| Boldrey, EB | 5 |
| Enot, KJ | 4 |
| Pischer, TL | 3 |
| Seager, M | 1 |
| Elashoff, RM | 1 |
| Drafts, D | 1 |
| Bitran, JD | 1 |
| Desser, RK | 1 |
| DeMeester, TR | 1 |
| Colman, M | 1 |
| Evans, R | 1 |
| Billings, A | 1 |
| Griem, M | 1 |
| Rubenstein, L | 1 |
| Shapiro, C | 1 |
| Golomb, HM | 1 |
| Ertel, IJ | 2 |
| Boesel, C | 1 |
| Heiss, WD | 1 |
| Turnheim, M | 1 |
| Mamoli, B | 1 |
| Chernik, NL | 1 |
| Posner, JB | 2 |
| Hoffman, WF | 1 |
| Seager, ML | 1 |
| Tsukada, Y | 1 |
| Higby, DJ | 1 |
| Bakshi, S | 1 |
| Reese, PA | 1 |
| Jennings, E | 1 |
| Buge, A | 2 |
| Pouillart, P | 2 |
| Hasegawa, H | 1 |
| Townsend, J | 1 |
| Reichenbach, W | 1 |
| Fricker, U | 1 |
| Wagner, HP | 1 |
| Hvizdala, E | 1 |
| Morgan, SK | 1 |
| Palangie, T | 1 |
| Huguenin, P | 1 |
| Morin, P | 1 |
| Gautier, H | 1 |
| Crist, WM | 1 |
| Vietti, TJ | 1 |
| Ducos, R | 1 |
| Chu, JY | 1 |
| Young, DF | 1 |
| Kumar, AR | 1 |
| Levin, V | 1 |
| Powell, M | 1 |
| Jovanovic, D | 1 |
| Djuric, LJ | 1 |
| Jevremovic, S | 1 |
| Mijatovic, LJ | 1 |
| Sneed, PK | 2 |
| Weaver, KA | 2 |
| Larson, DA | 2 |
| Hayani, A | 1 |
| Mahoney, DH | 1 |
| Taylor, LD | 1 |
| Gumerlock, MK | 1 |
| Belshe, BD | 1 |
| Madsen, R | 1 |
| Watts, C | 1 |
| Glass, J | 1 |
| Gruber, ML | 1 |
| Smith, D | 1 |
| Rattner, B | 1 |
| Coyle, T | 1 |
| Bushunow, P | 1 |
| Winfield, J | 1 |
| Wright, J | 1 |
| Graziano, S | 1 |
| Leibel, SA | 1 |
| Silver, P | 3 |
| Ahn, DK | 1 |
| Flam, MS | 1 |
| Goldman, DL | 1 |
| Dahlborg, SA | 2 |
| Crossen, J | 1 |
| Ramsey, F | 1 |
| Roman-Goldstein, S | 1 |
| Braziel, R | 1 |
| Dana, B | 1 |
| Ogilvy-Stuart, AL | 1 |
| Shalet, SM | 2 |
| Gattamaneni, HR | 1 |
| Hannigan, J | 1 |
| Hellman, RM | 1 |
| Calogero, JA | 1 |
| Kaplan, BM | 1 |
| Bradford, R | 1 |
| Gaspar, LE | 1 |
| Bagella, MP | 1 |
| Fadda, G | 1 |
| Cherchi, PL | 1 |
| Gill, PG | 1 |
| Abbott, RL | 1 |
| Ahmad, A | 1 |
| Zeicmanis, J | 1 |
| Stewart, DJ | 1 |
| Grahovac, Z | 1 |
| Hugenholtz, H | 1 |
| Russell, N | 1 |
| Richard, M | 1 |
| Benoit, B | 1 |
| Jenkin, RD | 1 |
| Boesel, CP | 1 |
| Venes, JL | 1 |
| Ortega, JA | 1 |
| Evans, AE | 1 |
| Hammond, D | 1 |
| Rodriguez, LA | 1 |
| Clayton, PE | 1 |
| Price, DA | 1 |
| Jones, PH | 1 |
| Djang, WT | 1 |
| Kurtzberg, J | 1 |
| Longee, DC | 1 |
| Halperin, EC | 1 |
| Falletta, JM | 1 |
| Coleman, RE | 1 |
| Oakes, WJ | 1 |
| Pfefferbaum, B | 1 |
| Pack, R | 2 |
| Brent, TP | 1 |
| von Hofe, E | 1 |
| Mitra, S | 1 |
| Swenberg, JA | 1 |
| Kleihues, P | 1 |
| Lichter, AS | 1 |
| Bunn, PA | 1 |
| Ihde, DC | 1 |
| Cohen, MH | 1 |
| Makuch, RW | 1 |
| Carney, DN | 1 |
| Johnston-Early, A | 1 |
| Minna, JD | 1 |
| Glatstein, E | 1 |
| Comella, G | 1 |
| Scoppa, G | 1 |
| De Marco, M | 1 |
| Ianniello, GP | 1 |
| Melillo, G | 1 |
| Coucourde, F | 1 |
| Zarrilli, D | 1 |
| Chak, LY | 1 |
| Zatz, LM | 1 |
| Wasserstein, P | 1 |
| Cox, RS | 1 |
| Kushlan, PD | 1 |
| Porzig, KJ | 1 |
| Sikic, BI | 1 |
| Gehan, EA | 1 |
| Vogel, FS | 1 |
| Al-Sarraf, M | 1 |
| Talley, RW | 1 |
| Costanzi, JJ | 1 |
| Athens, JW | 1 |
| Oishi, N | 1 |
| Fletcher, WS | 1 |
| Pendergrass, TW | 1 |
| Mulne, AF | 1 |
| Kosnik, EJ | 1 |
| Morris, JD | 1 |
| Heideman, RL | 1 |
| Ruymann, FB | 1 |
| Stuntz, JT | 1 |
| Bleyer, WA | 1 |
| Takaue, Y | 1 |
| Sullivan, MP | 1 |
| Ramirez, I | 1 |
| Cleary, KR | 1 |
| Borsi, J | 1 |
| Révész, T | 1 |
| Kardos, G | 1 |
| Kobayashi, T | 1 |
| Stokes, DC | 1 |
| Shenep, JL | 1 |
| Hughes, WT | 1 |
| Baram, T | 1 |
| Price, P | 1 |
| Thompson, H | 1 |
| Bessell, EM | 1 |
| Gershanovich, ML | 1 |
| Arkhipov, AI | 1 |
| Vilenskiĭ, BS | 1 |
| Olive, D | 1 |
| Philip, T | 1 |
| Zucker, JM | 1 |
| Czorny, A | 1 |
| Lapras, C | 1 |
| Brunat-Mentigny, M | 1 |
| Baram, TZ | 1 |
| Martinez-Prieto, J | 1 |
| Mahaley, MS | 1 |
| Whaley, RA | 1 |
| Krigman, MR | 1 |
| Bouldin, TW | 1 |
| Bertsch, L | 1 |
| Cush, S | 1 |
| Gurney, HP | 1 |
| Phadke, K | 1 |
| Afra, D | 1 |
| Kocsis, B | 1 |
| Kerpel-Fronius, S | 1 |
| Eckhardt, S | 1 |
| Setdikov, RA | 1 |
| Kruglova, GV | 1 |
| Bender, BL | 1 |
| Mayernik, DG | 1 |
| Sato, J | 1 |
| Ninomiya, T | 1 |
| Saijo, T | 1 |
| Akita, H | 1 |
| Miki, Y | 1 |
| Hirose, M | 1 |
| Hashimoto, T | 1 |
| Miyao, M | 1 |
| Matsumoto, K | 1 |
| Ashby, MA | 1 |
| Bowen, D | 1 |
| Watson, JV | 1 |
| Repetto, L | 1 |
| Grimaldi, A | 1 |
| Ardizzoni, A | 1 |
| Sertoli, MR | 1 |
| Rosso, R | 1 |
| Vera, R | 1 |
| Enriquez, R | 1 |
| Papac, R | 1 |
| Coody, D | 1 |
| Smith, B | 1 |
| Ettinger, LJ | 1 |
| Sinniah, D | 1 |
| Siegel, SE | 1 |
| Fishman, LS | 1 |
| Segall, HD | 1 |
| Soni, D | 1 |
| Bennetts, GA | 1 |
| Schultz, DH | 1 |
| Raphael, D | 1 |
| Paul, EA | 1 |
| Mott, TJ | 1 |
| Godlee, JN | 1 |
| Tobias, JS | 1 |
| Capra, LG | 1 |
| Collins, CD | 1 |
| Mooney, C | 1 |
| Bozek, T | 1 |
| Broder, LE | 1 |
| Rall, DP | 1 |
| Ivankovic, S | 1 |
| Vasantha Kumar, AR | 1 |
| Renaudin, J | 1 |
| Eagan, RT | 1 |
| Maurer, LH | 1 |
| Forcier, RJ | 1 |
| Tulloh, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Improvement of Functional Outcome for Patients With Newly Diagnosed Grade II or III Glioma With Co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 Trial[NCT05331521] | Phase 3 | 406 participants (Anticipated) | Interventional | 2021-04-07 | Recruiting | ||
| A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma[NCT00003375] | Phase 2/Phase 3 | 370 participants (Actual) | Interventional | 1998-10-31 | Completed | ||
| Evaluation of 18F-Fluciclovine PET-MRI as a Biomarker of Response in Pediatric and Young Adult Patients With Low Grade Gliomas (LGG)[NCT05555550] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA[NCT00002840] | Phase 3 | 350 participants (Anticipated) | Interventional | 1996-08-31 | Completed | ||
| Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas[NCT00002569] | Phase 3 | 299 participants (Actual) | Interventional | 1994-07-31 | Completed | ||
| Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old[NCT00002944] | Phase 3 | 428 participants (Actual) | Interventional | 1997-04-30 | Completed | ||
| A Prospective Cohort to Study the Effect of Postoperative Upfront Temozolomide Chemotherapy on IDH Mutational Low Grade Gliomas in Eloquent Areas[NCT02209428] | Phase 2 | 54 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| A Phase II， Single-arm Trail of Chidamide Combined With Rituximab and High-dose Methotrexate in Previously Untreated Patients With Primary Central Nervous System Lymphoma[NCT04516655] | Phase 2 | 51 participants (Anticipated) | Interventional | 2020-09-01 | Not yet recruiting | ||
| Phase Ⅱ Trial of Temozolomide Plus Concurrent Whole-Brain Radiation Followed by TNV Regimen as Adjuvant Therapy for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (PCNSL)[NCT01735747] | Phase 2 | 16 participants (Anticipated) | Interventional | 2008-06-30 | Active, not recruiting | ||
| PHASE II STUDY OF PREIRRADIATION PCV CHEMOTHERAPY IN PATIENTS WITH SUPRATENTORIAL LOW-GRADE GLIOMAS[NCT00002806] | Phase 2 | 43 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| Second Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors After PCV-Chemotherapy[NCT00003304] | Phase 2 | 29 participants (Anticipated) | Interventional | 1998-04-30 | Completed | ||
| A Phase I/II Study of Oral Procarbazine in the Treatment of Recurrent High Grade Astrocytomas[NCT00004004] | Phase 1/Phase 2 | 0 participants | Interventional | 1999-07-31 | Completed | ||
| A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas[NCT01445119] | Phase 1 | 58 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Phase II Randomized Sham-Controlled Trial With Allocation Concealment and Blinded Patients and Assessors, Investigating Hyperbaric Oxygen as a Radiation Sensitizer for Locally Advanced Squamous Cell Carcinoma of the Oropharynx and Larynx[NCT03843671] | Phase 2 | 400 participants (Anticipated) | Interventional | 2019-07-01 | Not yet recruiting | ||
| Does Varenicline Influence Alcohol Consumption in Alcohol Dependent Individuals?[NCT00846859] | Phase 2 | 162 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas: The Glioma Molecular Diagnostic Initiative[NCT00031538] | 674 participants (Actual) | Observational | 2002-03-01 | Terminated | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
45 reviews available for procarbazine and Brain Neoplasms
| Article | Year |
|---|---|
Treatment Options for Recurrent Primary CNS Lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms | 2022 |
Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2020 |
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Dis | 2017 |
[Management of gliomas].
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2014 |
Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma.
Topics: Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Clinical Trials, Phase III as T | 2014 |
Low-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2015 |
Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen?
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Humans; Lomustine; Ol | 2015 |
Low-grade and anaplastic oligodendroglioma.
Topics: Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; DNA Modification Methyl | 2016 |
Procarbazine--a traditional drug in the treatment of malignant gliomas.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cli | 2008 |
[Clinicopathological diagnosis of gliomas by genotype analysis].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
Chemotherapy for diffuse low-grade gliomas in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chemother | 2011 |
Chemotherapy in low-grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Clinical Trials | 2012 |
Conformal irradiation for pure and mixed oligodendroglioma: the experience of Centre Leon Berard Lyon.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Damage, Chronic; Brain Injuries | 2003 |
Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2003 |
[Gliomatosis cerebri: report of 3 cases and review of recent literatures].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Diagnosis, Diff | 2003 |
The role of PCV chemotherapy in the treatment of central neurocytoma: illustration of a case and review of the literature.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Humans; Lomusti | 2003 |
Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Cranial Irradia | 2004 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
[The molecular genetics of oligodendroglioma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromos | 2004 |
Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; | 2005 |
[Brief review of the neuro oncology for recent three decades in Japan].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain; Brain Neoplasms; Humans; | 2005 |
[Resent advances in chemotherapy for malignant brain tumors].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brai | 2005 |
The role of chemotherapy in the treatment of low-grade glioma. A review of the literature.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Proca | 2005 |
Anaplastic oligodendroglioma and oligoastrocytoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brai | 2007 |
[Recent developments in chemotherapy of malignant diseases].
Topics: Anthraquinones; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 1982 |
Glioblastoma multiforme: pathology, natural history and treatment.
Topics: Adolescent; Adult; Aged; Antigens, Neoplasm; Antigens, Surface; Astrocytoma; Brain Neoplasms; Carmus | 1984 |
Chemotherapy of brain metastases: current status.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Humans; Injections, S | 1984 |
Aggressive oligodendroglioma: a chemosensitive tumor.
Topics: Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Ad | 1994 |
Cerebral non-Hodgkin's lymphoma discovered when treating Hodgkin's disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Carmustine; Cyc | 1993 |
Chemotherapy for malignant gliomas.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, D | 1996 |
Acute leukemia following treatment of malignant glioma.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Fatal Outcome | 1998 |
Primary intracerebral Hodgkin's disease: report of a case with Epstein-Barr virus association and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain; Brain Neoplasms; Combined | 1999 |
Chemotherapy of low-grade gliomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chi | 2001 |
Multidisciplinary management of adult anaplastic oligodendrogliomas and anaplastic mixed oligo-astrocytomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; G | 2001 |
PCV chemotherapy for oligodendroglioma: response analyzed on T2 weighted-MRI.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M | 2001 |
[Chemo-radiotherapy for malignant brain tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Central Nervous System | 2002 |
Adults with newly diagnosed high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Antioxidan | 2001 |
Chemotherapy in the treatment of malignant brain tumors.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cyclophosphami | 1975 |
Chemotherapy: the agents in current use.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Glioma; | 1975 |
Hypersensitivity reactions to procarbazine with mechlorethamine, vincristine, and procarbazine chemotherapy in the treatment of glioma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Drug Hypersensit | 1992 |
Aggressive oligodendroglioma: a chemosensitive tumor.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Crani | 1992 |
Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Child; Child, Preschool; Female; Glioblastoma; Glioma; Hum | 1989 |
The role of radiation therapy in the treatment of small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Clinical Tri | 1985 |
Principles of brain tumor chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; | 1986 |
Chemotherapy of brain tumors.
Topics: Adult; Antineoplastic Agents; Azaguanine; Bleomycin; Brain Neoplasms; Child; Cyclophosphamide; Drug | 1972 |
100 trials available for procarbazine and Brain Neoplasms
| Article | Year |
|---|---|
Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Neoplasm | 2022 |
New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brai
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biomarkers, Tu | 2013 |
Early response to high-dose methotrexate, vincristine, and procarbazine chemotherapy-adapted strategy for primary CNS lymphoma: no consolidation therapy for patients achieving early complete response.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Brain Neoplasms; Disease-Fr | 2014 |
Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2014 |
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chi-Square Distr | 2014 |
Patients with primary brain tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Che | 2014 |
Joint modeling of longitudinal health-related quality of life data and survival.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Hu | 2015 |
Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Cr | 2016 |
The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazin | 2016 |
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined Modali | 2016 |
Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Child, Preschoo | 2016 |
[Not Available].
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chemoradiotherapy; Dis | 2016 |
When temozolomide alone fails: adding procarbazine in salvage therapy of glioma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Magnetic R | 2008 |
Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cell Proliferation; Ch | 2009 |
Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cognition; Combined Mo | 2010 |
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant | 2009 |
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2009 |
Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carbopl | 2010 |
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M | 2010 |
Impact of adjuvant chemotherapy for gliomatosis cerebri.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 2010 |
Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Chr | 2011 |
Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined | 2011 |
Phase II trial of radiotherapy after hyperbaric oxygenation with multiagent chemotherapy (procarbazine, nimustine, and vincristine) for high-grade gliomas: long-term results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain N | 2012 |
A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Brain Neoplasms; Female; Follow-Up Studies; G | 2012 |
Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Central Nervous System | 2012 |
Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Disease-Fre | 2013 |
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chromosomes, Hum | 2013 |
Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chemoradi | 2013 |
Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC stu
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemothera | 2013 |
Concurrent modified PCV chemotherapy and radiotherapy in newly diagnosed grade IV astrocytoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined Modali | 2002 |
Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chromosome Aber | 2003 |
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2003 |
Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astro | 2003 |
Tolerance of nitrosurea-based multiagent chemotherapy regime for low-grade pediatric gliomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Chi | 2003 |
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2003 |
Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2004 |
Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Bromodeoxyuridine; Che | 2004 |
Randomized controlled trial on malignant brain tumors--activities of the Japan Clinical Oncology Group-Brain Tumor Study Group.
Topics: Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Glioblastoma; Humans | 2004 |
Initial chemotherapy in gliomatosis cerebri.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2004 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytom | 2004 |
Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Cognition; Combined Modality | 2005 |
A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group.
Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Alkyl and Aryl Transferases; Antineoplastic | 2006 |
Oligodendroglial tumor chemotherapy using "decreased-dose-intensity" PCV: a Singapore experience.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; | 2006 |
PCV chemotherapy for recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; D | 2006 |
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brai | 2006 |
A pilot study of dose-intensified procarbazine, CCNU, vincristine for poor prognosis brain tumors utilizing fibronectin-assisted, retroviral-mediated modification of CD34+ peripheral blood cells with O6-methylguanine DNA methyltransferase.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2006 |
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant | 2006 |
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer p
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant | 2006 |
Feasibility and response to 1-(4-amino-2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride chemotherapy with pre-treated procarbazine for elderly patients with newly diagnosed glioblastoma.
Topics: Aged; Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Benzylisoquinolines; Brain Neoplasm | 2007 |
Phase II trial of radiotherapy after hyperbaric oxygenation with chemotherapy for high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Ther | 2006 |
Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; Disease | 2007 |
Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2008 |
Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2007 |
A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Busulfan; Combi | 2008 |
Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery. A Southwest Oncology Group Report.
Topics: Brain Neoplasms; Combined Modality Therapy; Drug Therapy, Combination; Female; Glioblastoma; Humans; | 1983 |
Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Small Cell; Cyclophosphamide; Doxoru | 1982 |
Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Administration | 1983 |
Evaluation of CCNU, VM-26 plus CCNU, and procarbazine in supratentorial brain gliomas. Final evaluation of a randomized study. European Organization for Research on Treatment of Cancer (EORTC) Brain Tumor Group.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Drug Therapy, Combination; Female; | 1981 |
Primary intracranial gliomas: clinical studies and treatment regimens of the Brain Tumor Research Center, University of California, San Francisco, 1977-1979.
Topics: Antineoplastic Agents; Brain Neoplasms; California; Carmustine; Clinical Trials as Topic; Drug Thera | 1981 |
A review of studies of the EORTC brain tumor group.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dexamethasone; Drug Administration | 1981 |
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemother | 1995 |
Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm | 1995 |
Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Canada; Ce | 1994 |
Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combi | 1994 |
Ototoxicity in children with malignant brain tumors treated with the "8 in 1" chemotherapy protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; | 1996 |
Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool | 1997 |
TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 1997 |
Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas.
Topics: Adult; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; | 1997 |
Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine--a phase-II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Female; Glioblastoma; H | 1998 |
Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Female; Glioma; | 1998 |
Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr | 1998 |
Effect of etoposide on the pharmacokinetics of methotrexate in vivo.
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combi | 1998 |
Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain; Brain N | 1999 |
A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brain | 1999 |
Combined treatment modality for anaplastic oligodendroglioma: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; D | 1999 |
A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Bromodeoxyuridine; Che | 1999 |
Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2000 |
Quantitative 201Tl SPET imaging in the follow-up of treatment for brain tumour: a sensitive tool for the early identification of response to chemotherapy?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Female; Follow- | 2000 |
A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antin | 2000 |
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2000 |
Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; | 2000 |
Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemotherapy, Adjuvant | 2001 |
Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr | 2000 |
Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte 06-alkylguanine-DNA alkyltransferase activity.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Lymphocytes; Male; Midd | 2001 |
Response and progression in recurrent malignant glioma.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Aged, 80 and over; Alitretinoin; Antineoplastic Combine | 1999 |
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm | 2002 |
BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, C | 1976 |
[A study of the use of sequential chemotherapy in 176 cases of glioblastoma (author's transl)].
Topics: Adult; Brain Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combination; Follow-Up | 1978 |
Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma | 1992 |
Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine, and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined | 1992 |
External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain Neoplasms; Combine | 1991 |
Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Bro | 1991 |
Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 1990 |
The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chi | 1989 |
The role of radiation therapy in the treatment of small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Clinical Tri | 1985 |
Randomized comparisons of radiotherapy and carmustine versus procarbazine versus dacarbazine for the treatment of malignant gliomas following surgery: a Southwest Oncology Group Study.
Topics: Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glio | 1986 |
Phase I trial of procarbazine as a 5-day continuous infusion in children with central nervous system tumors.
Topics: Brain Neoplasms; Child; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Male; Procarbazin | 1987 |
Randomized phase III trial of single versus multiple chemotherapeutic treatment following surgery and during radiotherapy for patients with anaplastic gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Clinical Trials as Topi | 1987 |
Combination chemotherapy with cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) in children with brain tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool | 1985 |
189 other studies available for procarbazine and Brain Neoplasms
| Article | Year |
|---|---|
Early Postoperative Treatment versus Initial Observation in CNS WHO Grade 2 and 3 Oligodendroglioma: Clinical Outcomes and DNA Methylation Patterns.
Topics: Adult; Brain Neoplasms; DNA Methylation; Humans; Isocitrate Dehydrogenase; Lomustine; Methyltransfer | 2022 |
T2-Fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Magnetic Resonan | 2023 |
Salvage chemotherapy after failure of targeted therapy in a child with BRAF V600E low-grade glioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child, Preschool; Glioma; Humans; L | 2021 |
A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Glioma; Humans; | 2020 |
Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Humans; Lomustine; Pro | 2021 |
One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Drug-Related Side Effects an | 2021 |
PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Neoplasm Staging | 2021 |
Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Cost-Bene | 2017 |
Chemotherapy of Diffuse Astrocytoma (WHO grade II) in Adults.
Topics: Adult; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Humans; Procarbazi | 2018 |
Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2018 |
Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2018 |
PCV for anaplastic oligodendrogliomas: back to the future or a step backwards? A point/counterpoint discussion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2013 |
How to use molecular markers when caring for a patient with brain cancer: 1P/19Q as a predictive and prognostic marker in the neuro-oncology clinic.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosome Deletion; Chromosomes, H | 2013 |
Anaplastic oligodendroglioma: a new treatment paradigm and current controversies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Female; | 2013 |
Advantages of dose-dense methotrexate protocol for primary central nervous system lymphoma: comparison of two different protocols at a single institution.
Topics: Academies and Institutes; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic C | 2013 |
Longitudinal quality of life data: a comparison of continuous and ordinal approaches.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Appetite; Brain Neoplas | 2014 |
Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Disease Progression; Drug Therapy, Combination; Femal | 2015 |
Comparative efficacy of bevacizumab and PCV chemotherapy in recurrent glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; | 2015 |
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Second-Line Chemotherapy in Recurrent Glioblastoma: A 2-Cohort Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothe | 2015 |
PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astr | 2015 |
Successful Treatment of Bing-Neel Syndrome Accompanying Waldenström's Macroglobulinemia with R-MPV: A Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Humans; Lymphoma, Large B-C | 2015 |
High-grade glioma in children and adolescents: a single-center experience.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astro | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of High-Grade Glioma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Beva | 2015 |
Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Protocols; Clinical | 2015 |
Chemotherapy for intracranial ependymoma in adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dis | 2016 |
[Pediatric ependymomas: Current diagnosis and therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Ependymoma; Humans; Infant; | 2016 |
Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2008 |
Procarbazine and CCNU as initial treatment in gliomatosis cerebri.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; | 2008 |
Retrospective analysis of treatment outcome in 315 patients with oligodendroglial brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Chi | 2009 |
Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
Bevacizumab is active as a single agent against recurrent malignant gliomas.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Glioma; Humans; Lomustine; | 2010 |
Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Central Nervous System | 2011 |
Testicular lymphoma, intraocular (vitreoretinal) lymphoma, and brain lymphoma: involvement of three immunoprivileged sites in one patient.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chr | 2011 |
Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated patients with recurrent glioblastoma: a single-institution analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Chemotherapy and radiotherapy combination extends survival for patients with oligodendroglial tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Proliferation; Chemoradiothera | 2012 |
Intensified PCV-chemotherapy with optional stem cell support in recurrent malignant oligodendroglioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Brain Neoplasms; Female | 2002 |
Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Femal | 2002 |
Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl | 2002 |
Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl | 2002 |
Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl | 2002 |
Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl | 2002 |
Dramatic response to chemotherapy in oligodendroglial gliomatosis cerebri.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Corpus Callosum; Fro | 2003 |
Long-term sequelae in children treated for brain tumors: impairments, disability, and handicap.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Brain; Brain Damage, Chronic; B | 2003 |
Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosome Aberrations; Chromosomes | 2003 |
Interobserver variability in the radiological assessment of response to chemotherapy in glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2003 |
[Use of modern technologies in the diagnosis and combined treatment of brain stem tumors].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2003 |
Determination of procarbazine in human plasma by liquid chromatography with electrospray ionization mass spectrometry.
Topics: Antineoplastic Agents; Brain Neoplasms; Chromatography, High Pressure Liquid; Clinical Trials, Phase | 2004 |
Monitoring individual response to brain-tumour chemotherapy: proton MR spectroscopy in a patient with recurrent glioma after stereotactic radiotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Astrocytoma; Brain Neoplasms; | 2004 |
Long-term outcome of oligodendrogliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Ci | 2004 |
[Neoadjuvant chemotherapy for symptomatic non operable grade II fibrillary astrocytoma in adults].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Astrocytom | 2004 |
Gliomatosis cerebri: better definition, better treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Astrocyt | 2004 |
Treatment of low-grade oligodendroglial tumors without radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Combined Modal | 2004 |
Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neo | 2005 |
Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Humans; Lomust | 2005 |
Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm | 2005 |
Toxic epidermal necrolysis after PCV combination chemotherapy for relapsed B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Lymphoma, B-Cell | 2006 |
Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Case-Control Studies; | 2006 |
Anaplastic oligodendroglial tumors: a tale of two trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Tr | 2006 |
Spontaneously relapsing and remitting primary CNS lymphoma in an immunocompetent 45-year-old man.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Central Nervous System Neop | 2006 |
Gliomatosis cerebri treatment in 11 elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M | 2006 |
High-grade glioma in children under 5 years of age: a chemotherapy only approach with the BBSFOP protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child, Preschool; Cisp | 2006 |
Genetic and metabolic predictors of chemosensitivity in oligodendroglial neoplasms.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosomes, | 2006 |
Astrocytic tumors in children: treatment results from a single institution.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Chi | 2007 |
[Long-term outcome in patients with symptomatic low-grade oligodendrogliomatous tumors treated by cytotoxic agents].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemo | 2006 |
Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemothera | 2007 |
Osmotic blood-brain barrier modification and combination chemotherapy: concurrent tumor regression in areas of barrier opening and progression in brain regions distant to barrier opening.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; B | 1984 |
Late results of multimodality therapy of high-grade supratentorial astrocytomas.
Topics: Adult; Antineoplastic Agents; Astrocytoma; Bleomycin; Brain Neoplasms; Drug Therapy, Combination; Fe | 1981 |
Primitive neuroectodermal tumors of childhood. An approach to therapy.
Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Dexamethasone; Drug Therapy, | 1981 |
Long term survival among patients with malignant brain tumors.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Female; Glioblastoma; Humans; M | 1982 |
Treatment of small cell lung cancer: intensive remission induction, radiation therapy, and maintenance chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Small Cell; Doxorubicin; Drug Therap | 1982 |
Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and systemic chemotherapy for malignant gliomas: a follow-up study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 1983 |
Intraoperative radiotherapy in childhood malignant astrocytoma.
Topics: Brain Neoplasms; Carmustine; Child; Combined Modality Therapy; Glioblastoma; Humans; Intraoperative | 1984 |
Successful treatment of primary central nervous system lymphomas with chemotherapy after osmotic blood-brain barrier opening.
Topics: Adult; Aged; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cyclophosphamide; Dexameth | 1983 |
Procarbazine, CCNU and vincristine (PCV) combination chemotherapy for brain tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined Modali | 1984 |
Therapeutic benefits of combination chemotherapy with vincristine, BCNU, and procarbazine on recurrent cystic craniopharyngioma. A case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Craniopharyngiom | 1984 |
Complications associated with intra-arterial BCNU administered in combination with vincristine and procarbazine for the treatment of malignant brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1984 |
Combination chemotherapy with vincristine (NSC-67574), procarbazine (NSC-77213), prednisone (NSC-10023) with or without nitrogen mustard (NSC-762)(MOPP vs OPP) in children with recurrent brain tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Follow-Up | 1984 |
[Second tumor following Hodgkin's disease].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child, Presc | 1984 |
The failure of human leukocyte interferon to influence the growth of human glioma cell populations: in vitro and in vivo studies.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; | 1983 |
Intracerebral growth of a human glioma tumor line in athymic mice and treatment with procarbazine, 1,3-bis(2-chloroethyl)-1-nitrosourea, aziridinylbenzoquinone, and cis-platinum.
Topics: Animals; Antineoplastic Agents; Aziridines; Azirines; Benzoquinones; Brain Neoplasms; Carmustine; Ce | 1983 |
Two cases of acute leukemia following treatment of malignant glioma.
Topics: Acute Disease; Adult; Astrocytoma; Brain Neoplasms; Female; Glioma; Humans; Leukemia; Nitrosourea Co | 1983 |
Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft model.
Topics: Animals; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cell Line; Glioma; Humans; Medullob | 1982 |
[Results of combined modality treatment of malignant gliomas. Comparison of postoperative irradiation, chemotherapy, and combined radio-polychemotherapy (author's transl)].
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Therapy, Combination; Female; Glioma; Huma | 1981 |
Heterogeneous response to chemotherapy of human gliomas grown in nude mice and as clones in vitro.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Clone Cells; Glioma; Humans; Kinetics; Mice; Mice, | 1981 |
Response and control: lessons from oligodendroglioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Oligodendrogliom | 1995 |
Chemoradiation and adjuvant chemotherapy for glioblastoma: why does so much therapy yield so little improvement in survival?
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemotherapy, Adjuvant | 1995 |
Interleukin-2 gene therapy in a patient with glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cells, Cultured; Combined Modality | 1995 |
[Survival of children with primitive neuroectodermal tumors and malignant ependymomas of the central nervous system after treatment with 8 cytostatic agents in one day. A report of the Children's Cancer Group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cytarabine; Ependymoma; | 1995 |
Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Carmustine; Ch | 1994 |
p53 mutations, O6-alkylguanine DNA alkyltransferase activity, and sensitivity to procarbazine in human brain tumors.
Topics: Animals; Base Sequence; Brain Neoplasms; Cell Cycle; DNA Mutational Analysis; DNA Repair; Genes, p53 | 1995 |
Brain tumor chemotherapy trials: slow start, but quickly gaining.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials as Topic; Humans; L | 1994 |
Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Childrens Cancer Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Cyclophospha | 1994 |
Long survival in patients with acquired immune deficiency syndrome-related primary central nervous system lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; C | 1994 |
Aplastic anemia induced by cyclohexylchloroethylnitrousurea.
Topics: Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Blood Cell Cou | 1994 |
Prognostic factors in malignant gliomas with special reference to intra-arterial chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 1993 |
Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; Procarbazine | 1993 |
The treatment of malignant scala posterior tumors in children: II. Preliminary result of the pre- and postoperative adjuvant chemotherapy of scala posterior tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain; Brain Neoplasms; Chemotherapy, A | 1993 |
Low-grade oligodendroglioma responds to chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Humans; Lomustine; M | 1996 |
Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas.
Topics: Adult; Astrocytoma; Brain Neoplasms; Female; Humans; Lomustine; Male; Middle Aged; Procarbazine; Pro | 1996 |
Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Pr | 1996 |
MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cerebellar Neoplasms; Chemotherapy, | 1997 |
Radiation and chemotherapy improve outcome in oligodendroglioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1997 |
Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors.
Topics: Adult; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain | 1997 |
Duke researchers link brain tumor drug resistance to mismatch repair deficiency.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; DNA Damage; DNA Repair; DNA, Neoplasm; Drug Resista | 1997 |
Treatment of high-risk medulloblastoma and other primitive neuroectodermal tumors with reduced dose craniospinal radiation therapy and multi-agent nitrosourea-based chemotherapy.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Al | 1996 |
[Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Gl | 1997 |
Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 1998 |
Bihemispheric malignant glioma: one size does not fit all.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Fatal Outcome; Glioblastoma; | 1998 |
CCNU overdose during PCV chemotherapy for anaplastic astrocytoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neo | 1998 |
Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 1998 |
A retrospective study of the value of chemotherapy as adjuvant therapy to surgery and radiotherapy in grade 3 and 4 gliomas.
Topics: Administration, Oral; Adult; Age Distribution; Antineoplastic Combined Chemotherapy Protocols; Brain | 1998 |
Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Fem | 1999 |
AIDS-related central nervous system lymphomas.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neopl | 1999 |
BUdR radiosensitization in anaplastic astrocytoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Bromodeoxyuridine; Che | 1999 |
Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors.
Topics: Adult; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carbamazepi | 1999 |
Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Carmustine; Chemotherapy | 1999 |
Chemosensitivity in childhood brain tumours in vitro: evidence of differential sensitivity to lomustine (CCNU) and vincristine.
Topics: Adult; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Child; Dose-Response Relationship, Drug; | 2000 |
Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2001 |
Successful combination chemotherapy (vincristine, procarbazine, etoposide, and prednisolone) in the treatment of inoperable, radioresistant low grade astrocytoma: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Etoposide; Fema | 2000 |
Myeloablative chemotherapy for recurrent aggressive oligodendroglioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplanta | 2000 |
Efficacy of adjuvant therapy with procarbazine, MCNU, and vincristine for oligodendroglial tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chemotherapy, A | 2001 |
PCV chemotherapy for recurrent glioblastoma multiforme.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; Female; Gliobl | 2001 |
Medical Research Council adjuvant trial in high-grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant | 2001 |
Medroxyprogesterone acetate alone or synergistic with chemotherapy suppresses colony formation and DNA synthesis in C6 glioma in vitro.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Death; | 2001 |
Radiotherapy combined with procarbazine, bleomycin, and CCNU in the treatment of high-grade supratentorial astrocytomas.
Topics: Adolescent; Adult; Aged; Astrocytoma; Bleomycin; Brain Neoplasms; Child; Drug Therapy, Combination; | 1978 |
Single-agent chemotherapy of brain tumors. A five-year review.
Topics: Astrocytoma; Bone Marrow Diseases; Brain Neoplasms; Carmustine; Glioma; Humans; Imidazoles; Lomustin | 1976 |
Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP)--effective four-drug combination chemotherapy for metastatic non-oat cell bronchogenic carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Bone Neoplasms; Brain Neoplasms; C | 1976 |
Brain tumors in children.
Topics: Adolescent; Astrocytoma; Brain; Brain Neoplasms; Child; Diagnosis, Differential; Ependymoma; Female; | 1978 |
Combination chemotherapy of malignant glioma. Effect of postoperative treatment with CCNU, vincristine, amethopterine and procarbazine.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Drug Therapy, Combination; Glioma; Humans; Lomustine; Meth | 1978 |
Human brain tumor transplantation into nude mice.
Topics: Animals; Brain Neoplasms; Carmustine; Glioblastoma; Humans; Mice; Mice, Nude; Neoplasm Transplantati | 1979 |
BCNU-5-fluorouracil combination therapy for recurrent malignant brain tumors.
Topics: Astrocytoma; Bone Marrow; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glio | 1978 |
Chemotherapy of nonirradiated malignant gliomas. Phase II: study of the combination of methyl-CCNU, vincristine, and procarbazine.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Brain Neoplasms; Drug Evaluation; Drug Therapy, Com | 1979 |
Chemotherapy of experimental metastatic brain tumors in female Wistar rats.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carcinoma 256, Walker; Carotid Arteries; Cells, Cul | 1979 |
Development of Hodgkin's disease in a patient receiving procarbazine, CCNU, and vincristine therapy for a gemistocytic astrocytoma.
Topics: Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Drug Therapy, Combination; Female; Hodgkin Dise | 1978 |
Response to vincristine and Procarbazine of recurrent medulloblastomas. Report of 2 cases.
Topics: Brain; Brain Neoplasms; Child; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male; Med | 1978 |
Combination chemotherapy with MOPP in children with recurrent brain tumors.
Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Child; Child, Preschool; Drug Therapy, Combinati | 1978 |
Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine.
Topics: Adolescent; Adult; Brain Neoplasms; Child; Child, Preschool; Drug Therapy, Combination; Humans; Lomu | 1978 |
Treatment of adult malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Administration Schedule; Drug Therapy, Com | 1978 |
Chemotherapy of childhood medulloblastoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Brain Neoplasms; Child; Cyclophosphamide; Dexamethasone; D | 1976 |
Nitrosourea chemotherapy for primary malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glioma; Humans; Lomustine; Neo | 1976 |
Chemotherapy of malignant glioma with CCNU alone and CCNU combined with vincristine sulfate and procarbazine hydrochloride.
Topics: Brain Neoplasms; Drug Evaluation; Drug Therapy, Combination; Glioma; Humans; Lomustine; Nitrosourea | 1976 |
Chemotherapy of primary malignant brain tumors in children.
Topics: Antineoplastic Agents; Brain Neoplasms; Brain Stem; Carmustine; Child; Ependymoma; Glioma; Humans; M | 1975 |
Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors.
Topics: Brain Neoplasms; Drug Therapy, Combination; Evaluation Studies as Topic; Humans; Lomustine; Neoplasm | 1975 |
Brachytherapy of brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain Neoplasms; Child; Combined Moda | 1992 |
Therapy-related myelodysplastic syndrome in children with medulloblastoma following MOPP chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool | 1992 |
Osmotic blood-brain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: patient series and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Cyclophosphami | 1992 |
The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Drug Admi | 1992 |
Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Cogniti | 1991 |
Thyroid function after treatment of brain tumors in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine | 1991 |
Chemotherapy for oligodendroglioma. Progress report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Neoplasm Recurre | 1991 |
VP-16, vincristine and procarbazine with radiation therapy for treatment of malignant brain tumors.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Etoposide; Female; Glioblastom | 1990 |
Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Drug Eval | 1990 |
The chemotherapeutic response of a murine (VM) model of human glioma.
Topics: Animals; Astrocytoma; Brain Neoplasms; Carmustine; Disease Models, Animal; Lomustine; Mice; Mice, In | 1990 |
Successful chemotherapy for newly diagnosed aggressive oligodendroglioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Humans; Lomustine; M | 1990 |
Non-Hodgkin lymphoma: a rare primary vulvar localization.
Topics: Brain Neoplasms; Drug Therapy, Combination; Female; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Pred | 1990 |
Effective palliation of melanoma with procarbazine and radiotherapy given by a low-dose fractionation schedule.
Topics: Brain Neoplasms; Combined Modality Therapy; Humans; Lymphatic Metastasis; Male; Melanoma; Palliative | 1986 |
Combined intraarterial and systemic chemotherapy for intracerebral tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; | 1987 |
Ovarian function following chemotherapy for childhood brain tumours.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child; Chil | 1989 |
Criteria for termination of phase II chemotherapy for patients with progressive or recurrent brain tumor.
Topics: Adolescent; Antineoplastic Agents; Astrocytoma; Aziridines; Benzoquinones; Brain Neoplasms; Cohort S | 1989 |
Monoamine oxidase inhibitor toxicity.
Topics: Brain Neoplasms; Child; Female; Glioma; Humans; Procarbazine; Substance-Related Disorders | 1989 |
O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts.
Topics: Animals; Brain Neoplasms; Drug Resistance; Glioma; Humans; Medulloblastoma; Methyltransferases; Mice | 1989 |
Radiotherapy and combination chemotherapy with carmustine, vincristine, and procarbazine (BVP) in primary brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1985 |
Neurologic dysfunction in patients treated for small cell carcinoma of the lung: a clinical and radiological study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Diseases; Brain Neoplasms; | 1986 |
Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Cisplatin; Comb | 1987 |
Second malignant neoplasm in treated Hodgkin's disease. Report of a patient and scope of the problem.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Combined Modality Therapy; G | 1986 |
Chemotherapy administered in conjunction with osmotic blood-brain barrier modification in patients with brain metastases.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barr | 1987 |
New drug combination for the treatment of relapsed brain tumors in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool | 1988 |
[New developments in chemotherapy for experimental brain metastasis].
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Daunorubicin; Doxorubicin; Flo | 1985 |
Presentation of Pneumocystis carinii pneumonia as unilateral hyperlucent lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child, Preschool; Huma | 1988 |
Renal impairment following the combined use of high-dose methotrexate and procarbazine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Humans; | 1988 |
[Use of nitrosourea derivatives in the treatment of patients with Hodgkin's disease with lesions of the central nervous system].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Drug Evaluation; | 1988 |
Successful chemotherapy for recurrent malignant oligodendroglioma.
Topics: Adult; Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Female; Humans | 1988 |
[Efficacy of the "8 drugs in a day" protocol in brain tumors in children].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cer | 1988 |
Salvage chemotherapy for recurrent primary brain tumors in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Chi | 1988 |
Treatment of recurrent esthesioneuroblastoma with combined intra-arterial chemotherapy. A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Female; Humans; Infusio | 1987 |
Hodgkin's disease presenting with central nervous system involvement.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Hodgkin Disease; Humans; Mal | 1987 |
Dibromodulcitol-based combined postoperative chemotherapy of malignant astrocytomas and glioblastomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined | 1986 |
[Clinical picture, diagnosis and treatment of the brain lesions in lymphosarcomas].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M | 1986 |
Hodgkin's disease presenting with isolated craniospinal involvement.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; D | 1986 |
[Combination chemotherapy with MOPP and intrathecal methotrexate in children with brain tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Choroid Pl | 1986 |
Intracranial Hodgkin's disease: a primary presentation and access of cytotoxic agents.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chlorambucil; Combined | 1986 |
Metastatic malignant melanoma treated with procarbazine, vincristine and lomustine (POC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Female | 1987 |
Hodgkin's disease, intracranial involvement. Report of a case and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Hodgkin Disease; Humans; Mal | 1985 |
MOPP regimen as primary chemotherapy for brain tumors in infants.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cerebellar Neoplasms; | 1985 |
Assay of anti-cancer drugs in tissue culture: relationship of relapse free interval (RFI) and in vitro chemosensitivity in patients with malignant cerebral glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cells, Cultured; Female; Gli | 1985 |
Chemosensitivity testing in the treatment of malignant gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Glioma; Humans; Lomustine; Procarba | 1985 |
[Induction of malignomas in rats after transplacental exposure to N-isopropyl-alpha-2-(methyl-hydrazino)-p-toluamide-HCl].
Topics: Animals; Antineoplastic Agents; Benzoates; Brain Neoplasms; Female; Fetus; Gestational Age; Maternal | 1972 |
Procarbazine hydrochloride in the treatment of brain tumors. Phase 2 study.
Topics: Adolescent; Adult; Anticonvulsants; Astrocytoma; Brain Neoplasms; Child; Electroencephalography; Epe | 1974 |
Proceedings: Small cell carcinoma of the lung: staging, paraneoplastic syndromes, treatment, and survival.
Topics: Bone Marrow; Bone Neoplasms; Brain Neoplasms; Carcinoma; Cyclophosphamide; Drug Therapy, Combination | 1974 |